

NHS BLOOD AND TRANSPLANT

NATIONAL LIVER OFFERING SCHEME

NINETY-SIX MONTH REVIEW

SUMMARY

1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity.
- 1.2. It should be noted that this report may not include all data due to delays in reporting.
- 1.3. Updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and the changes to the DBD offering scheme ceased on 9 July 2020 when named patient offering recommenced. This period is excluded from part of the liver offering section.
- 1.5. The estimates used to calculate the Transplant Benefit Score (TBS) were updated on 4 October 2022 and the offering data has been presented separately for 2022/2023. One of the factors (inpatient status) identified as statistically significant in the non-cancer models was set to zero on 23rd May 2023 following discussion at the prior NLOS monitoring committee and LAG Core Group.

2. DATA AND METHODS

- 2.1. **Table S1** shows the time period and inclusion and exclusion criteria for the aspects of the offering scheme examined in this report. NHS Group 2 registrations and transplants were excluded throughout the report along with registrations, offers and transplants for intestinal patients not requiring a liver. Super-urgent and elective registrations were included in all aspects apart from the transplant list activity section as were adult and paediatric registrations and transplants. All full year time periods are 20 March to 19 March.

Table S1	Inclusion and exclusion criteria for the aspects of NLOS examined in this report		
Section	Time period	Inclusions	Exclusions
Registration activity	20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1169) 20 March 2018 to 19 March 2026 (<i>ninety-six months post</i>, N=9282)	New active/suspended registrations	- Dublin registrations - NHS Group 2 registrations
One and three month post-registration outcome	20 December 2014 to 19 December 2017 (<i>Year prior</i>, N=2779) 20 March 2018 to 19 December 2025 (<i>ninety-three months post</i>, N=7437)	- Active and suspended - Adult elective liver and liver/kidney registrations	- Dublin registrations - NHS Group 2 registrations - Intestinal registrations
Six months post-registration outcome	20 September 2014 to 19 September 2017 (<i>Year prior</i>, N=2781) 20 March 2018 to 19 September 2025 (<i>ninety months post</i>, N=7190)	- Active and suspended - Adult elective liver and liver/kidney registrations	- Dublin registrations - NHS Group 2 registrations - Intestinal registrations
One-year post-registration outcome	20 March 2014 to 19 March 2017 (<i>Year prior</i>, N=2808) 20 March 2018 to 19 March 2025 (<i>eighty-four months post</i>, N=6703)	- Active and suspended - Adult elective liver and liver/kidney registrations	- Dublin registrations - NHS Group 2 registrations - Intestinal registrations
Two-year post-registration outcome	20 March 2014 to 19 March 2016 (<i>Year prior</i>, N=1884) 20 March 2018 to 19 March 2024 (<i>seventy-two months post</i>, N=5770)	- Active and suspended - Adult elective liver and liver/kidney registrations	- Dublin registrations - NHS Group 2 registrations - Intestinal registrations
Liver offering	<i>Year prior</i>, N=1914 (962 DBD and 952 DCD) <i>Ninety months post</i>, N=13735 (6465 DBD and 7270 DCD)	- UK deceased donors whose liver was offered for transplantation - Offers to Dublin for super-urgent patients	- Intestinal offers regardless of whether patients required a liver - Offers declined due to the patient accepting previously offered liver - Offers to Dublin for elective patients
Transplant activity	20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=1017, 819 DBD and 198 DCD) <i>Ninety-six months post</i>, N=7069 (5192 DBD and 1877 DCD)	UK transplants	- Transplants performed at Dublin - Intestinal transplants for patients not requiring a liver - NHS Group 2 transplants
Ninety-day post-transplant survival	20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD) 20 March 2018 to 19 December 2025 (<i>Ninety-three months post</i>, N=3476 for DBD and 1661 for DCD)	UK adult elective liver and liver/kidney transplants	- Txs performed at Dublin - Intestinal transplants for patients not requiring a liver - NHS Group 2 transplants
One-year post-transplant survival	20 March 2017 to 19 March 2018 (<i>Year prior</i>, N=579 for DBD and 183 for DCD) 20 March 2018 to 19 March 2025 (<i>Eighty-four months post</i>, N=3219 for DBD and 1417 for DCD)	UK adult elective liver and liver/kidney transplants	- Txs performed at Dublin - Intestinal transplants for patients not requiring a liver - NHS Group 2 transplants

3. RESULTS

REGISTRATION ACTIVITY

- 3.1. There were 9282 new NHS Group 1 liver registrations in the UK in the first ninety-six months of the scheme. (**Table 1**)
- 3.2. The proportion of elective liver registrations has remained around 90% in the first ninety-six months post-NLOS. The proportion of adult elective registrations with CLD has decreased slightly to 69% in 2025/26 and was 71% in 2017/18. The proportion of HCC registrations (including HCC downstaging) was 19% in the most recent period (2025/26). The proportion of new variant syndrome registrations in 2017/18 and 2025/26 was 9% and 10% respectively. (**Table 3**)
- 3.3. Ninety-two percent of the new adult elective registrations in 2025/26 were for first graft compared with 91% in 2017/2018. (**Table 4**)
- 3.4. The median age of new adult elective registrations was 55 in 2017/2018 and varies between 54 and 56 in the ninety-six months post-NLOS. The median age for variant syndrome registrations has decreased to 46.5 years in 2025/26. (**Table 5**)

POST-REGISTRATION OUTCOMES

- 3.5. There were 6703 adult elective registrations in the subset of patients registered in the first 84 months post-NLOS. The proportion of registrations who received a transplant within one year of registration ranged from 59% to 74% across the yearly time periods post NLOS, with 64% of those registered in 2024/25 transplanted within one-year of registration. (**Table 6**)
- 3.6. The proportion of patients who either died on the list or were removed due to condition deterioration in the first year of listing ranged from 6% to 12% in the time periods post NLOS compared to 10% to 11% in the time period prior. In the two-year registration outcome time periods, the proportion of patients who either died on the list or were removed due to condition deterioration ranged from 9% to 14% in the time periods post NLOS compared to 12% to 14% in the time period prior. (**Figures 6 and B4**).

LIVER OFFERING

- 3.7. Overall, 6465 DBD and 7270 DCD livers were offered in the first ninety-six months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 93% in the 96 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 57% for the 96 months post and 32% in the year prior to NLOS. (**Table 8**).
- 3.8. **Figures 9a** and **9b** in the main paper show the number of DBD livers offered during the first ninety-six months at each stage of the liver offering pathway. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. 1082 livers were either

accepted and transplanted or declined and not offered on prior to the elective section of the offering pathway.

- 3.1. Of the 5159 DBD livers offered to the elective section that were not offered only to paediatric centres and not offered during the first wave of COVID-19 in 2020, 4642 (90%) were allocated to the elective CLD/HCC pathway while 517 (10%) were randomly allocated to the variant syndrome pathway which is consistent with the percentages used in the probabilistic prioritisation of the elective list.
- 3.2. 2516 livers (not accepted by higher tiers) offered to named elective CLD/HCC were accepted and transplanted while 219 livers offered to the named elective variant syndrome pathway were accepted and transplanted.
- 3.3. 2101 livers declined by all stages were fast-tracked and 815 were accepted and transplanted.
- 3.4. 10356 (31%) of the 32889 offers made in the first 96 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 7097 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.5. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 34 with a median of two offers per patient.
- 3.6. Seventy three patients at 7 centres were offered 11 or more livers in the 96 month time period (19 were offered 11 livers, 18 were offered 12 livers, 12 were offered 13 livers, 9 were offered 14 livers, 3 were offered 15 livers, 1 was offered 16, 2 were offered 17, 3 were offered 18 livers, 1 was offered 19 livers, 1 was offered 21, 2 were offered 27, 1 was offered 29 and 1 was offered 34 livers). Ten of the 73 patients offered 11 or more livers in the 96 month time period were on the variant syndrome pathway, 4 were on the HCC pathway and 59 were on the CLD pathway.

TRANSPLANT ACTIVITY

- 3.7. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). Between 20 March 2025 and 19 March 2026, 8% of transplants were super-urgent (**Table 14**).
- 3.8. One hundred and forty adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the transplant section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients.
- 3.9. For DBD transplants, there was evidence of a statistically significant association between time period and age group ($p=0.00158$), type of patient ($p<0.0001$), disease group ($p=0.00010$),

transplant centre ($p=0.00064$), blood group compatibility ($p=0.00343$), zonal ($p<0.0001$) and blood group matching ($p<0.0001$) (**Table 15**).

- 3.10. For DCD transplants, there was evidence of a statistically significant association between time period and age group ($p=0.03561$), type of patient ($p=0.00114$), disease group ($p<0.0001$), transplant centre ($p<0.0001$) and there was no significance for blood group compatibility ($p=0.13206$) or zonal ($p=0.09470$) at the 5% level. (**Table 16**).
- 3.11. There was a statistically significant difference in cold ischaemia time for both adult elective DBD ($p=0.001$) and DCD ($p<0.001$) transplants across the time periods of interest. However, this may be due to the inclusion of periods of machine perfusion which is not currently collected on the liver transplant record form. (**Figures 16-19**)
- 3.12. There was no significant difference in ninety-day DBD and DCD patient survival ($p\text{-value}=0.34$ and 0.08 respectively). (**Figure 20**). There was no significant difference in ninety-day transplant survival for either DBD and DCD transplants (log-rank $p\text{-value}=0.73$ and 0.52). (**Figure 21**).
- 3.13. There was no significant difference in one-year DBD and DCD patient survival ($p\text{-value}=0.45$ and 0.63 respectively). (**Figure 22**). There was no significant difference in one-year transplant survival for either DBD or DCD transplants ($p\text{-value}=0.91$ and 0.81 respectively). (**Figure 23**).

NHS BLOOD AND TRANSPLANT

NATIONAL LIVER OFFERING SCHEME

NINETY-SIX MONTH REVIEW

1. BACKGROUND

- 1.1. The new National Liver Offering Scheme (NLOS) was introduced on 20 March 2018 for donation after brain death (DBD) donors and mainly for liver offers to named patients. Offering of livers from donors after circulatory death (DCD) has not changed and remains on a centre-specific basis rather than on a patient specific basis. This report examines the impact of the new DBD scheme on patients on the waiting list, livers offered and transplant activity. All full year time periods are 20 March to 19 March.
- 1.2. It should also be noted that this report may not include all data due for the first ninety-six months due to delays in reporting.
- 1.3. The updated Kidney Offering Scheme and Pancreas Offering Scheme were introduced on 11 September 2019. Unfortunately, an unexpected and untested change was introduced to the NLOS at the same time which affected the number of patients that appeared as named elective patients on matching run. This change was removed on the 19 September 2019 and this report includes this period in all analyses apart from in the flow chart in **Figure 9B**.
- 1.4. Due to the impact of COVID-19, it was agreed by OTDT Medical team and the Liver Advisory Group chair on 27 March 2020 that liver centres should consider an elective named patient offer for any patient when offered and not just the named patient. It was also agreed that a kidney would not be held back if a liver/kidney patient was in the top 3 named elective patients. There were no changes to the DCD offering scheme and NLOS resumed on 9 July 2020.
- 1.5. Birmingham, Royal Free, Kings College and Cambridge temporarily closed for all adult transplants in December 2020/January 2021. Royal Free and Birmingham temporarily transferred some of their clinically urgent patients to other transplant centres who were open. Transplant centres reviewed their transplant lists in January 2021 and formally suspended non-urgent patients. Offering to named clinically urgent patients continued and centres could consider livers for non-urgent patients if declined for all clinically urgent patients.
- 1.6. All transplant centres other than Birmingham formally reactivated all non-urgent CLD and HCC patients on the 6th April 2021 while variant syndrome patients and patients at Birmingham were reactivated in late April 2021.

- 1.7. Birmingham closed for all DCD offers in January 2021 with Newcastle and Leeds receiving Birmingham's zonal and linked offers on a rota basis. Birmingham reopened for DCD offers in late April 2021.
- 1.8. The parameter estimates and baseline survivor functions used to calculate the TBS were updated on 4 October 2022. One of the factors (inpatient status) identified as statistically significant in the non-cancer models was set to zero on 23rd May 2023 following discussion at the prior NLOS monitoring committee and LAG Core Group.

2. DATA AND METHODS

2.1. REGISTRATION ACTIVITY AND POST-REGISTRATION OUTCOME

- 2.1.1. Data on 10451 new active/suspended NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 March 2026 were obtained from the UK Transplant Registry on 10 April 2026. Patients registered in Dublin or as NHS Group 2 were excluded as such elective patients would only be offered a liver if all UK transplant centres declined the offer.
- 2.1.2. One and three month registration outcomes were examined, by year, for registrations either between 20 December 2014 and 19 December 2017 (N=2779) or between 20 March 2018 and 19 December 2025 (N=7437).
- 2.1.3. Six month registration outcome was examined for registrations either between 20 September 2014 and 19 September 2017 (N=2781) or between 20 March 2018 and 19 September 2025 (N=7190).
- 2.1.4. One-year registration outcome was examined for registrations either between 20 March 2014 and 19 March 2017 (N=2808) or between 20 March 2018 and 19 March 2025 (N=6703). Two-year registration outcome was examined for a subset registered either between 20 March 2014 and 19 September 2016 (N=1884) or between 20 March 2018 and 19 March 2024 (N=5770).

2.2. LIVER OFFERING

- 2.2.1. Data on 15649 deceased donors (7427 DBD and 8222 DCD) from the UK whose liver was offered for transplantation between 20 March 2017 and 19 March 2026 were obtained from the UK Transplant Registry on 23 April 2026. Intestinal offers were excluded regardless of whether they required a liver or not. The data was split into nine year periods.

2.3. TRANSPLANT ACTIVITY AND POST-TRANSPLANT SURVIVAL

- 2.3.1. Data on 8,086 deceased donor liver transplants (6,011 DBD and 2,075 DCD) performed in the UK between 20 March 2017 and 19 March 2026 were also obtained from the UK Transplant Registry on 10 April 2026. Intestinal transplants involving the liver were included.

3. RESULTS

3.1. REGISTRATION ACTIVITY - OVERALL

3.1.1. **Figure 1** shows the number of new NHS Group 1 registrations on the UK liver transplant list between 20 March 2017 and 19 March 2026 by quarter and urgency status while **Table 1** compares the twelve months pre the introduction of NLOS and the ninety-six months post the introduction of NLOS. There was no statistically significant association between the time of registration and registration type (Chi-squared p-value =0.28). It should be noted that there was an increase in the number of paediatric acute liver failure patients in the first two quarters of 2022.




Table 1 Urgency status by time period for all NHS Group 1 liver registrations in the UK, 20 March 2017 to 19 March 2026										
Urgency status	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26	Total
Elective	1035 (89)	1074 (88)	1064 (89)	908 (90)	1115 (91)	1108 (88)	1018 (90)	1022 (90)	1001 (90)	9345 (89)
Super-urgent	134 (11)	140 (12)	132 (11)	104 (10)	109 (9)	149 (12)	118 (10)	112 (10)	108 (10)	1106 (11)
Total	1169 (100)	1214 (100)	1196 (100)	1012 (100)	1224 (100)	1257 (100)	1136 (100)	1134 (100)	1109 (100)	10451 (100)

REGISTRATION ACTIVITY - SUPER-URGENT

3.1.2. **Table 2** compares the twelve months pre the introduction of NLOS and the ninety six months post the introduction of NLOS by super-urgent category.

The proportion of patients registered as either category 8 (HAT on days 0 to 21) or 9 (Early graft dysfunction on days 0 to 7) was 26% in the year prior and ranged between 18% and 28% in the years post NLOS and was 28% in 2025/26. **Appendix A** shows the descriptions of each of the categories.

Table 2 Super-urgent category by time period for super-urgent registrations in the UK, 20 March 2017 to 19 March 2026

Super-urgent category	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26	Total
1	2 (1)	3 (2)	4 (3)	3 (3)	5 (5)	5 (3)	3 (3)	0 (0)	1 (1)	26 (2)
2	11 (8)	10 (7)	11 (8)	5 (5)	5 (5)	14 (9)	11 (9)	6 (5)	8 (7)	81 (7)
3	4 (3)	9 (6)	6 (5)	9 (9)	7 (6)	8 (5)	5 (4)	7 (6)	11 (10)	66 (6)
4	2 (1)	2 (1)	2 (2)	3 (3)	4 (4)	1 (1)	8 (7)	4 (4)	7 (6)	33 (3)
5	11 (8)	5 (4)	3 (2)	4 (4)	8 (7)	10 (7)	2 (2)	8 (7)	6 (6)	57 (5)
6	54 (40)	56 (40)	50 (38)	41 (39)	40 (37)	59 (40)	36 (31)	42 (38)	32 (30)	410 (37)
7	6 (4)	3 (2)	9 (7)	8 (8)	10 (9)	10 (7)	10 (8)	5 (4)	5 (5)	66 (6)
8	22 (16)	19 (14)	14 (11)	9 (9)	8 (7)	19 (13)	19 (16)	17 (15)	20 (19)	147 (13)
9	13 (10)	20 (14)	15 (11)	11 (11)	12 (11)	10 (7)	12 (10)	10 (9)	10 (9)	113 (10)
10	4 (3)	4 (3)	6 (5)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)	1 (1)	19 (2)
20	3 (2)	5 (4)	7 (5)	6 (6)	5 (5)	5 (3)	5 (4)	9 (8)	3 (3)	48 (4)
88	2 (1)	4 (3)	5 (4)	5 (5)	5 (5)	7 (5)	5 (4)	3 (3)	4 (4)	40 (4)
Total	134 (100)	140 (100)	132 (100)	104 (100)	109 (100)	149 (100)	118 (100)	112 (100)	108 (100)	1106 (100)

3.2. REGISTRATION ACTIVITY - ELECTIVE

3.2.1. **Table 3** compares the twelve months pre the introduction of NLOS and the ninety-six months post the introduction of NLOS for NHS Group 1 elective registrations by age and type of patient. There was no statistically significant association between patient age group and time period (Chi-squared p-value =0.61).

Table 3 Type of elective patient by time period for elective registrations in the UK, 20 March 2017 to 19 March 2026

Type of patient Overall	2017/18 1035	2018/19 1074	2019/20 1064	2020/21 908	2021/22 1115	2022/23 1108	2023/24 1018	2024/25 1022	2025/26 1001	Total 9345
<i>Adult elective¹</i>	951 (92)	989 (92)	980 (92)	825 (91)	1038 (93)	1016 (92)	927 (91)	932 (91)	929 (93)	8587 (92)
CLD	674 (71)	720 (73)	738 (75)	635 (77)	786 (76)	741 (73)	654 (71)	658 (71)	641 (69)	6247 (73)
HCC/ HCC downstaging	193 (20)	195 (20)	178 (18)	147 (18)	168 (16)	169 (17)	164 (18)	161 (17)	174 (19)	1549 (18)
Variant syndrome	83 (9)	71 (7)	56 (6)	39 (5)	63 (6)	83 (8)	82 (9)	90 (10)	90 (10)	657 (8)
ACLF	0 (0)	1 (0)	3 (0)	2 (0)	15 (1)	20 (2)	27 (3)	23 (2)	24 (3)	115 (1)
Liver/ cardiothoracic	1 (0)	2 (0)	5 (1)	2 (0)	6 (1)	3 (0)	0 (0)	0 (0)	0 (0)	19 (0)
<i>Paediatric elective²</i>	84 (8)	85 (8)	84 (8)	83 (9)	77 (7)	92 (8)	91 (9)	90 (9)	72 (7)	758 (8)
Hepatoblastoma/ Prioritised Paediatric	3 (4)	10 (12)	10 (12)	21 (25)	16 (21)	20 (22)	19 (21)	20 (22)	11 (15)	130 (17)
Non hepatoblastoma	81 (96)	74 (87)	74 (88)	62 (75)	59 (77)	72 (78)	72 (79)	70 (78)	61 (85)	625 (82)
Liver/ cardiothoracic	0 (0)	1 (1)	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)	0 (0)	0 (0)	3 (0)

¹ Includes 21 CLD, 1 HCC and 5 Variant syndrome patient aged 17 years or over and weighing 40kg or under (1 in the twelve months prior and 26 in the ninety months post); 21 were dual-listed as small adults (1 in the twelve months prior and 20 in the ninety-six months post)

² Includes 10 hepatoblastoma tier, 127 non hepatoblastoma and 2 liver/cardiothoracic patients aged less than 17 years and weighing 40kg or over (20 in the twelve months prior and 119 in the ninety months post); 113 were dual-listed as large paediatrics (5 in the twelve months prior and 108 in the ninety-six months post)

- 3.2.2. **Table 4** compares the twelve months pre and the ninety-six months post the introduction of NLOS for each type of adult patient registered over the last 108 months by transplant number. The majority of patients were registered for a first liver transplant and there were no statistically significant associations between whether patient was registered for a first transplant or not and the time period (Chi-squared p-value=0.49).
- 3.2.3. All but four of the HCC patients were registered for a first graft. Three patients registered for a second graft had a UKELD less than 49 and no current ascites; two of the three patients had no encephalopathy and one had encephalopathy grade 1. One patient registered for a second graft had UKELD greater than 49, no current ascites, and no encephalopathy.
- 3.2.4. **Table 5** compares the median and interquartile age at registration for the twelve months pre and the ninety-six months post the introduction of NLOS for each type of adult patient registered over the last 108 months. There were no statistically significant differences in the median recipient age (Kruskal-Wallis p-value $\geq$ 0.36).

Table 4 Transplant number by time period for adult elective registrations in the UK, 20 March 2017 to 19 March 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26	Total
CLD¹ (Chi-squared p-value=0.53)										
1 st graft	597 (89)	651 (90)	654 (89)	567 (89)	720 (92)	674 (91)	593 (91)	590 (90)	575 (90)	5621 (90)
2 nd graft	64 (9)	57 (8)	71 (10)	58 (9)	48 (6)	56 (8)	56 (9)	57 (9)	53 (8)	520 (8)
3 rd graft	9 (1)	12 (2)	11 (1)	9 (1)	16 (2)	10 (1)	5 (1)	11 (2)	13 (2)	96 (2)
4 th graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	0 (0)	0 (0)	0 (0)	9 (0)
6 th graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
HCC/HCC downstaging² (Fishers exact p-value=0.95)										
1 st graft	192 (99)	194 (99)	178 (100)	147 (100)	168 (100)	168 (99)	164 (100)	160 (99)	174 (100)	1545 (100)
2 nd graft	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	4 (0)
Variant syndrome³ (Chi-squared p-value=0.09)										
1 st graft	73 (88)	61 (86)	55 (98)	36 (92)	59 (94)	80 (96)	78 (95)	85 (94)	81 (90)	608 (93)
2 nd graft	10 (12)	10 (14)	0 (0)	3 (8)	3 (5)	3 (4)	3 (4)	5 (6)	9 (10)	46 (7)
3 rd graft	0 (0)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)	3 (0)
Overall adult elective⁴ (Chi-squared p-value=0.49)										
1 st graft	863 (91)	909 (92)	895 (91)	754 (91)	967 (93)	945 (93)	861 (93)	857 (92)	852 (92)	7903 (92)
2 nd graft	75 (8)	68 (7)	71 (7)	61 (7)	51 (5)	60 (6)	60 (6)	64 (7)	63 (7)	573 (7)
3 rd graft	9 (1)	12 (1)	12 (1)	9 (1)	18 (2)	10 (1)	6 (1)	11 (1)	14 (2)	101 (1)
4 th graft	3 (0)	0 (0)	2 (0)	1 (0)	2 (0)	1 (0)	0 (0)	0 (0)	0 (0)	9 (0)
6 th graft	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Total	951 (100)	989 (100)	980 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	932 (100)	929 (100)	8587 (100)

The p-values above compare first graft and retransplant registrations by time period

¹ One patient dual-listed was registered for a second graft in the twelve months prior whilst six were registered for a first graft, five for a second graft, three for a third graft and one for a fourth graft in the ninety-six months post.

² Includes HCC downstaging all of whom were registered for first graft.

³ Three patients dual-listed were registered for first graft and two for a second graft in the ninety-six months post.

⁴ Includes liver and cardiothoracic patients (all of whom were registered for first graft) and hepatoblastoma tier patients (all whom were registered for a first graft except for one registered for a third graft).

Table 5 Median (IQR) age by time period for adult elective NHS Group 1 registrations in the UK, 20 March 2017 to 19 March 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26	Total
CLD¹ (Kruskal-Wallis p-value=0.47)										
N	674	720	738	635	786	741	654	658	641	6247
Median (IQR)	53 (44 - 61)	54 (44 - 61)	54 (45 - 61)	54 (43 - 61)	54 (43 - 60)	55 (44 - 61)	54 (44 - 61)	55 (43 - 60)	54 (43 - 61)	54 (44 - 61)
Range	17 - 76	17 - 73	17 - 74	17 - 71	17 - 74	17 - 71	17 - 71	17 - 74	17 - 72	17 - 76
HCC/HCC downstaging (Kruskal-Wallis p-value=0.55)										
N	193	195	178	147	168	169	164	161	174	1549
Median (IQR)	60 (55 - 65)	61 (56 - 65)	61 (55 - 66)	60 (56 - 64)	60 (56 - 65.5)	62 (57 - 65)	61 (57 - 65)	62 (57 - 65)	62 (57 - 66)	61 (56 - 65)
Range	20 - 74	21 - 73	21 - 72	19 - 73	43 - 73	37 - 72	27 - 72	34 - 72	18 - 71	18 - 74
Variant syndrome (Kruskal-Wallis p-value=0.48)										
N	83	71	56	39	63	83	82	90	90	657
Median (IQR)	49 (38 - 55)	51 (41 - 58)	48.5 (37.5 - 57.5)	48 (39 - 58)	48 (36 - 56)	48 (37 - 58)	50 (38 - 58)	51.5 (43 - 58)	46.5 (38 - 55)	49 (38 - 57)
Range	17 - 71	18 - 70	18 - 70	19 - 66	17 - 71	17 - 72	17 - 69	19 - 68	17 - 66	17 - 72
Overall adult elective² (Kruskal-Wallis p-value=0.36)										
N	951	989	980	825	1038	1016	927	932	929	8587
Median (IQR)	55 (46 - 62)	56 (47 - 62)	55 (47 - 62)	55 (45 - 61)	54.5 (45 - 61)	56 (46 - 62)	55 (45 - 62)	56 (45 - 61)	55 (45 - 62)	55 (46 - 62)
Range	17 - 76	17 - 73	17 - 74	17 - 73	17 - 74	17 - 72	17 - 72	17 - 74	17 - 72	17 - 76

¹ There was one patient dual-listed in the twelve months prior and 20 in the ninety-six months post² Includes liver and cardiothoracic patients and hepatoblastoma tier patients

3.3. POST-REGISTRATION OUTCOME

- 3.3.1. **Table 6** shows the one and three-month registration outcome for adult elective NHS Group 1 liver patients registered during the ninety-three months since the implementation of the NLOS, 20 March 2018 -19 December 2025, along with the prior thirty-six month period, 20 December 2014 – 19 December 2017. Note that the 2025/26 period covers 9 months due to time to follow-up.
- 3.3.2. There were 933 adult elective registrations in 2024/25 and 367 (39%) received a transplant within 3 months of registration. The corresponding three-month transplant rate for patients registered during the twelve months in 2016/17 is 49%. There were statistically significant differences between the time periods and registration outcome at one month and three month (Chi-squared p-value<0.0001).
- 3.3.3. **Table 6** also shows the six-month registration outcome for adult elective patients registered during the ninety months since the implementation of the NLOS, 20 March 2018 -19 March 2025, along with the prior thirty-six month period, 20 September 2014 – 19 September 2017. There were statistically significant differences between the time periods and registration outcome at six months (Chi-squared p-value<0.0001). In the first six months of 2025/26, 268 (55%) of the 487 registrations were transplanted within 6 months compared with 62% in 2016/17. The proportion of patients who either died on the list or were removed due to condition deterioration within six months was 5% compared with 8% in 2016/17.
- 3.3.4. **Table 6** also shows the one-year and two-year registration outcomes. The proportion of adults transplanted within twelve months was 64% in 2024/25 and the proportion of adults who either died on the list or were removed due to condition deterioration within twelve months remains around 8%.

Table 6 Registration outcome for adult elective NHS Group 1 registrations on the UK liver transplant list, 20 March 2014 to 19 December 2025											
Registration outcome	2014/15 ¹	2015/16 ¹	2016/17 ¹	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24 ²	2024/25 ²	2025/26 ²
One-month outcome (Chi-squared p-value<0.0001)											
Remained active/suspended	760 (82)	704 (77)	657 (70)	625 (63)	647 (66)	568 (69)	749 (72)	736 (72)	698 (75)	690 (74)	535 (73)
Died/ removed due to CD ³	25 (3)	19 (2)	21 (2)	14 (1)	10 (1)	20 (2)	16 (2)	23 (2)	11 (1)	18 (2)	9 (1)
Removed - other reasons	3 (0)	4 (0)	4 (0)	10 (1)	7 (1)	15 (2)	18 (2)	19 (2)	17 (2)	15 (2)	12 (2)
Transplanted	137 (15)	183 (20)	262 (28)	337 (34)	314 (32)	222 (27)	255 (25)	238 (23)	201 (22)	210 (23)	178 (24)
Total	925 (100)	910 (100)	944 (100)	986 (100)	978 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	933 (100)	734 (100)
Three-month outcome (Chi-squared p-value<0.0001)											
Remained active/suspended	539 (58)	470 (52)	410 (43)	419 (42)	458 (47)	426 (52)	576 (55)	581 (57)	527 (57)	507 (54)	397 (54)
Died/ removed due to CD ³	56 (6)	44 (5)	55 (6)	32 (3)	27 (3)	39 (5)	34 (3)	42 (4)	29 (3)	41 (4)	23 (3)
Removed - other reasons	11 (1)	9 (1)	12 (1)	18 (2)	15 (2)	23 (3)	22 (2)	24 (2)	23 (2)	18 (2)	17 (2)
Transplanted	319 (34)	387 (43)	467 (49)	517 (52)	478 (49)	337 (41)	406 (39)	369 (36)	348 (38)	367 (39)	297 (40)
Total	925 (100)	910 (100)	944 (100)	986 (100)	978 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	933 (100)	734 (100)
Six-month outcome (Chi-squared p-value<0.0001)											
Remained active/suspended	367 (39)	312 (33)	242 (27)	275 (28)	319 (33)	288 (35)	419 (40)	427 (42)	377 (41)	367 (39)	182 (37)
Died/ removed due to CD ³	81 (9)	86 (9)	68 (8)	44 (4)	48 (5)	73 (9)	62 (6)	67 (7)	52 (6)	51 (5)	22 (5)
Removed - other reasons	23 (2)	20 (2)	30 (3)	29 (3)	21 (2)	37 (4)	29 (3)	34 (3)	38 (4)	27 (3)	15 (3)
Transplanted	462 (50)	525 (56)	565 (62)	638 (65)	590 (60)	427 (52)	528 (51)	488 (48)	460 (50)	488 (52)	268 (55)
Total	933 (100)	943 (100)	905 (100)	986 (100)	978 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	933 (100)	487 (100)
One-year outcome (Chi-squared p-value<0.0001)											
Remained active/suspended	181 (19)	168 (18)	132 (14)	153 (16)	187 (19)	167 (20)	280 (27)	253 (25)	237 (26)	213 (23)	
Died/ removed due to CD ³	109 (11)	97 (10)	101 (11)	64 (6)	76 (8)	95 (12)	89 (9)	96 (9)	75 (8)	71 (8)	
Removed - other reasons	50 (5)	40 (4)	38 (4)	42 (4)	33 (3)	56 (7)	55 (5)	60 (6)	46 (5)	50 (5)	
Transplanted	619 (65)	620 (67)	653 (71)	727 (74)	682 (70)	507 (61)	614 (59)	607 (60)	569 (61)	599 (64)	
Total	959 (100)	925 (100)	924 (100)	986 (100)	978 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)	933 (100)	
Two-year outcome (Chi-squared p-value<0.0001)											
Remained active/suspended	54 (6)	50 (5)		64 (6)	78 (8)	70 (8)	106 (10)	105 (10)	89 (10)		
Died/ removed due to CD ³	130 (14)	113 (12)		85 (9)	91 (9)	113 (14)	117 (11)	123 (12)	106 (11)		
Removed - other reasons	81 (8)	63 (7)		54 (5)	59 (6)	74 (9)	106 (10)	102 (10)	71 (8)		
Transplanted	694 (72)	699 (76)		783 (79)	750 (77)	568 (69)	709 (68)	686 (68)	661 (71)		
Total	959 (100)	925 (100)		986 (100)	978 (100)	825 (100)	1038 (100)	1016 (100)	927 (100)		
¹ 20 December 20XX to 19 December 20XY for one and three-month outcomes, 20 September 20XX to 19 September 20XY for six-month outcome and 20 March 20XX to 19 March 20XY for one-year and two-year outcomes ² 20 March 2025 - 19 December 2025 for one and three-month outcomes, 20 March 2025 to 19 September 2025 for six-month outcomes ³ Includes patients removed as registered onto super-urgent list											

3.3.5. **Figure 3a** and **Figure 3b** show the one-year and two-year registration outcome by quarter and type of adult elective patient. HCC downstaging registrations are included with HCC registrations. The proportion of CLD patients registered post NLOS and transplanted in the first year post-registration ranged between 55% and 80% compared with 58% and 78% of registrations in the three years prior to NLOS. There was a statistically significant association between one-year transplant rate and time period of registration for CLD patients and HCC/HCC downstaging patients (Chi-squared p-value<0.05) but not a two-years for HCC/ HCC downstaging patients (Chi-squared p-value=0.07). For Variant syndrome patients, 28% of one-year outcomes contained less than 5 patients so the p-value should be observed with caution.

3.3.6. Equivalent charts for three-month and six-month are presented in **Figure B1** and **Figure C1** in **Appendix B** and **Appendix C**.

Figure 3a One year registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 March 2014 to 19 March 2025







Figure 3b Two year registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 March 2014 to 19 March 2024



3.3.7. **Figure 4a** and **Figure 4b** show the one-year and two-year registration by quarter and age group. There was a statistically significant association (Chi-squared p-value<0.01) between one-year transplant rate and time period of registration for all age groups except for 17-24 years and two-year transplant rate and time period of registration for all age groups except for 17-24 years and 60+ years. For patients aged 17-24 years, 58% of one-year outcomes (55% of two-year outcomes) contained less than 5 patients so the p-value should be observed with caution. Equivalent charts for three-month and six-month are presented in **Figure B2** and **Figure C2** in **Appendix B** and **Appendix C**.



3.3.8. **Figure 5a and Figure 5b** show the one-year and two-year registration outcome by quarter and whether the patient was registered for a first graft or re-graft. The proportion of first graft patients registered post NLOS and transplanted in the first year post-registration ranges between 57 and 79% compared with 62 and 74% of registrations in the three years prior. The proportion of re-graft patients registered post NLOS and transplanted in the first year post-registration ranged between 27 and 71% compared with 50 and 78% of registrations in the three years prior. There was a statistically significant association between one-year transplant rate and time period of registration for patients registered for a first graft but not for re-graft patients (Chi-squared p-value <0.0001 and 0.18 respectively). There was a statistically significant association between two-year transplant rate and time period of registration for patients registered for a first graft and for patients registered for a re-graft (Chi-squared p-value <0.0001 and 0.04 respectively). Equivalent charts for three-month and six-month are presented in **Figure B3** and **Figure C3** in **Appendix B** and **Appendix C**.





Figure 5b Two year registration outcome for active elective liver and liver/kidney patients, by first transplant or re-graft, 20 March 2014 to 19 March 2024



3.3.9. **Figure 6a and Figure 6b** shows the one-year and two-year registration outcome by quarter and sex. There was a statistically significant association between transplant rate and time period of registration for male and female patients (Chi-squared p-value <0.0001). Equivalent charts for three-month and six-month are presented in **Figure B4** and **Figure C4** in **Appendix B** and **Appendix C** and show consistent results with the one-year outcome chart.

Figure 6a One year registration outcome for active elective liver and liver/kidney patients, by sex, 20 March 2014 to 19 March 2025






Figure 6b Two year registration outcome for active elective liver and liver/kidney patients, by sex, 20 March 2014 to 19 March 2024





3.3.11. One hundred and seventeen patients listed for a regrant, either on the list on 20 March 2018 or registered during the ninety-six months post NLOS, were removed from the transplant list (regardless of reason). **Table 7** shows the reasons for removal from the transplant list for each of the 117 patients.

Table 7 Reasons for removal for 117 regrant patients removed from the transplant list

Patient number	Centre	Month removed	Time from previous tx to re-registration	Active time on the list	Reason for removal	Other reasons given
1	6	March 2018	1940	2562	Condition deteriorated	Deterioration of Hocom therefore not fit for OLTX
2	6	April 2018	1245	2	Other	At patient's request
3	5	May 2018	527	212	Condition deteriorated	
4	5	May 2018	1178	266	Condition improved	
5	6	July 2018	1106	247	Condition improved	
6	5	August 2018	480	596	Condition deteriorated	
7	6	September 2018	1220	55	Condition deteriorated	Patient has developed lung cancer
8	6	December 2018	2799	24	Condition deteriorated	Has extra hepatic collections, needs addressing
9	3	February 2019	1903	337	Condition deteriorated	Further investigations required for anaemia and cardiac function
10	4	March 2019	2220	392	Condition improved	
11	5	April 2019	2736	6	Condition deteriorated	Patient has deteriorated and is no longer a transplant candidate.
12	6	June 2019	2564	74	Condition improved	
13	3	September 2019	158	150	Condition deteriorated	HCC in nodes outside liver
14	5	October 2019	3351	66	Condition deteriorated	Patient has developed multi-organ failure, rising lactate in the context of sepsis.
15	6	November 2019	5275	879	Condition deteriorated	Pt requires full assessment for retransplant now, after a long period of suspension on the waiting list since Aug 2018. Deemed medically too high risk to receive a transplant

16	3	December 2019	49	13	Condition improved	Clinically improving. No longer has an indication for transplant HCC metastases super urgent request sent through via National appeal.
17	7	January 2020	179	117	Condition deteriorated	
18	5	February 2020	7655	164	Condition deteriorated	
19	5	February 2020	808	604	Condition deteriorated	
20	4	February 2020	103	30	Condition improved	Patient now for palliative care in their local hospital
21	3	February 2020	645	93	Condition improved	
22	1	March 2020	6929	10	Condition deteriorated	
23	5	July 2020	2907	609	Condition deteriorated	
24	6	July 2020	5537	764	Other	Moved to su waiting list
25	3	September 2020	56	1	Condition improved	
26	5	March 2021	11009	927	Condition deteriorated	
27	2	April 2021	62	15	Other	
28	6	April 2021	710	3	Condition improved	Patient pyrexial; patient died
29	6	May 2021	5498	74	Condition deteriorated	
30	7	May 2021	10069	654	Condition deteriorated	
31	4	May 2021	26	0	Registered onto the super-urgent list	
32	4	June 2021	545	381	Condition deteriorated	Admitted to ITU. Aim to get patient off ITU and to discharge with palliative care Clinical condition improved since listing Patient went for transplant found to have malignancy therefore abandoned
33	5	June 2021	6249	84	Condition improved	
34	6	August 2021	128	11	Condition deteriorated	
35	6	October 2021	198	739	Condition improved	
36	7	October 2021	168	103	Condition deteriorated	Patient too sick for liver transplant Following MDT - majority of the team do not support transplant due to concerns with compliance
37	2	October 2021	468	82	Patient/non-compliant	
38	5	October 2021	320	90	Condition deteriorated	
39	5	November 2021	1642	62	Condition deteriorated	
40	3	November 2021	1617	6	Condition deteriorated	Deteriorated and patient not keen on transplant
41	5	November 2021	1866	1256	Condition deteriorated	
42	2	November 2021	6606	42	Condition improved	
43	6	December 2021	2649	457	Other	
44	1	December 2021	53	4	Condition deteriorated	Drinking alcohol whilst on the waiting list
45	6	January 2022	876	113	Condition improved	
46	6	March 2022	5352	32	Condition deteriorated	
47	2	April 2022	1463	185	Patient/non-compliant	
48	6	April 2022	1404	241	Condition improved	End of life care. Frailty. Refractory leg abscess. MOF.
49	4	May 2022	245	283	Condition improved	
50	5	June 2022	5910	698	Condition deteriorated	
51	3	July 2022	5802	65	Condition improved	
52	4	September 2022	513	448	Patient/non-compliant	No indication for transplant-improved
53	1	October 2022	271	58	Condition deteriorated	
54	6	October 2022	1014	396	Other	
55	3	November 2022	3707	481	Condition deteriorated	
56	5	November 2022	9577	481	Patient/non-compliant	No longer meets listing criteria
57	1	December 2022	47	156	Condition improved	
58	5	January 2023	6133	1069	Condition deteriorated	
59	6	January 2023	1620	187	Condition improved	
60	6	February 2023	661	40	Condition improved	Non-compliant
61	6	February 2023	2297	30	Condition improved	
62	6	February 2023	748	540	Condition improved	
63	2	March 2023	1585	76	Patient/Non-compliant	
64	3	April 2023	2395	699	Condition deteriorated	Patient stable, does not require transplant at this time.
65	7	April 2023	6700	1817	Other (please specify)	
66	6	April 2023	170	211	Condition improved	
67	3	May 2023	1624	4	Condition deteriorated/patient unfit/medical contra-indication	

68	2	May 2023	2394	413	Other (please specify)	No further episodes of cholangitis since removal of phytobezoar Nutritionally depleted and severely deconditioned.
69	5	September 2023	2000	30	Condition deteriorated	
70	6	September 2023	9232	808	Condition deteriorated	
71	7	September 2023	9211	118	Registered onto Super-Urgent list	
72	5	September 2023	308	339	Condition improved	De-list on co-morbidity profile.
73	4	October 2023	994	162	Condition improved	
74	3	October 2023	6783	804	Condition deteriorated	
75	6	October 2023	10617	1752	Condition deteriorated	
76	1	November 2023	280	494	Condition improved	
77	5	December 2023	1164	821	Condition deteriorated	
78	3	December 2023	2832	430	Condition improved	
79	5	December 2023	1246	4	Patient/Non-compliant	
80	5	January 2024	1463	429	Patient/Non-compliant	
81	6	January 2024	147	39	Condition deteriorated	
82	5	February 2024	785	1785	Condition deteriorated	HCC outside criteria Too well - recolltarised
83	3	February 2024	21	16	Registered onto Super-Urgent list	
84	5	March 2024	5299	336	Condition deteriorated	
85	6	March 2024	111	1018	Condition improved	
86	3	March 2024	2408	1126	Condition improved	
87	6	March 2024	2797	439	Condition deteriorated	
88	5	May 2024	296	48	Condition improved	
89	6	June 2024	3313	216	Condition deteriorated	
90	6	July 2024	2585	419	Condition deteriorated	
91	2	July 2024	680	7	Condition deteriorated	
92	5	September 2024	4968	413	Condition deteriorated	Diagnosed with oesophageal cancer Active rectal cancer Patient deteriorated No indication Deteriorated Patient has left the country
93	4	September 2024	48	37	Condition deteriorated	
94	5	September 2024	291	606	Condition improved	
95	5	October 2024	1361	937	Condition deteriorated	
96	4	October 2024	2573	11	Other (please specify)	
97	6	October 2024	7983	906	Condition improved	
98	3	November 2024	112	198	Condition improved	
99	5	November 2024	354	1063	Patient/parent request	
100	5	January 2025	4522	1080	Patient/non-compliant	
101	3	March 2025	10310	334	Condition deteriorated/patient unfit/medical contra-indication	
102	6	May 2025	972	7	Other (please specify)	To be super urgent listed
103	2	May 2025	9386	22	Condition improved	
104	5	June 2025	935	551	Condition improved	
105	6	June 2025	2235	470	Condition improved	
106	2	June 2025	4797	591	Patient unfit	MDT discussion, not fit for re-graft
107	4	July 2025	1561	527	Patient unfit	
108	6	July 2025	365	365	Condition improved	No indication due to improvement
109	2	August 2025	58	17	Patient unfit	
110	6	September 2025	712	495	Condition deteriorated/patient unfit/medical contra-indication	Poor engagement
111	3	September 2025	85	53	Condition improved	
112	6	September 2025	2469	200	Patient/non-compliant	
113	5	October 2025	7343	76	Condition deteriorated	Decreased mobility with increased frailty
114	5	November 2025	2487	1394	Condition deteriorated	
115	7	January 2026	3541	161	Condition deteriorated	Patient now too unfit for transplant
116	6	March 2026	6842	342	Condition improved	
117	5	March 2026	2754	1272	Condition deteriorated	Declined due to risk-benefit profile.

3.4. LIVER OFFERING

- 3.4.1. **Table 8A** and **Table 8B** shows the overall UK DBD and DCD liver offering outcome between 20 March 2017 and 19 March 2026, by donor type and time period. 6465 DBD and 7270 DCD livers were offered for transplantation in the first ninety-six months of the scheme. Of the DBD livers offered, 5698 (88%) were retrieved for the purposes of transplantation and 4882 (86%) were transplanted (all but 31 were transplanted in the UK). The proportion of DBD livers offered and retrieved is very similar to the percentage for the 12 months prior to the introduction of the new scheme. **Table 8A** and **Table 8B** also shows the liver offering outcome for donors where at least one solid organ was retrieved for the purposes of transplantation.
- 3.4.2. **Table 9A to 9E** shows, separately, the reasons for not offering, not retrieving and not transplanting livers by donor type and time period. The number in brackets are the corresponding values for solid organ donors where at least one organ was retrieved for the purposes of transplantation.

Table 8A DBD donor liver offering outcome, 20 March 2017 to 19 March 2026, as at 23 April 2026

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
1A. ALL DONORS									
Number donors	1067	1072	1070	875	882	830	860	728	694
Liver not offered for donation	105	72	68	81	78	59	66	61	61
Liver offered for donation	962	1000	1002	794	804	771	794	667	633
Liver not retrieved (% offered)	118 (12%)	143 (14%)	135 (13%)	120 (15%)	90 (11%)	75 (10%)	98 (12%)	59 (9%)	47 (7%)
Liver retrieved (% offered)	844 (88%)	857 (86%)	867 (87%)	674 (85%)	714 (89%)	696 (90%)	696 (88%)	608 (91%)	586 (93%)
Livers transplanted overseas (% retrieved)	4 (0%)	9 (1%)	3 (0%)	2 (0%)	6 (1%)	2 (0%)	5 (1%)	2 (0%)	2 (0%)
Livers transplanted in the UK (% retrieved)	765 (91%)	754 (88%)	735 (85%)	580 (86%)	604 (85%)	599 (86%)	564 (81%)	516 (85%)	499 (85%)
Liver not transplanted (% retrieved)	75 (9%)	94 (11%)	129 (15%)	92 (14%)	104 (15%)	95 (14%)	127 (18%)	90 (15%)	85 (15%)
Used for research (% not transplanted)	44 (59%)	52 (55%)	70 (54%)	22 (24%)	47 (45%)	41 (43%)	44 (35%)	42 (47%)	37
2. SOLID ORGAN DONORS									
Number donors	949	965	965	752	789	770	778	672	640
Liver not offered for donation	45	28	22	23	27	24	26	24	26
Liver offered for donation	904	937	943	729	762	746	752	648	614
Liver not retrieved (% offered)	60 (7%)	80 (9%)	76 (8%)	55 (8%)	48 (6%)	50 (7%)	56 (7%)	40 (6%)	28 (5%)
Liver retrieved (% offered)	844 (93%)	857 (91%)	867 (92%)	674 (92%)	714 (94%)	696 (93%)	696 (93%)	608 (94%)	586 (95%)
Livers transplanted overseas (% retrieved)	4 (0%)	9 (1%)	3 (0%)	2 (0%)	6 (1%)	2 (0%)	5 (1%)	2 (0%)	2 (0%)
Livers transplanted in the UK (% retrieved)	765 (91%)	754 (88%)	735 (85%)	580 (86%)	604 (85%)	599 (86%)	564 (81%)	516 (85%)	499 (85%)
Liver not transplanted (% retrieved)	75 (9%)	94 (11%)	129 (15%)	92 (14%)	104 (15%)	95 (14%)	127 (18%)	90 (15%)	85 (15%)
Used for research (% not transplanted)	44 (59%)	52 (55%)	70 (54%)	22 (24%)	47 (45%)	41 (43%)	44 (35%)	42 (47%)	37 (44%)

Table 8B DCD donor liver offering outcome, 20 March 2017 to 19 March 2026, as at 23 April 2026

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
1A. ALL DONORS									
Number donors	1164	1224	1275	717	1033	1059	1139	1065	1138
Liver not offered for donation	212	220	220	131	162	149	151	170	177
Liver offered for donation	952	1004	1055	586	871	910	988	895	961
Liver not retrieved (% offered)	652 (68%)	746 (74%)	768 (73%)	416 (71%)	558 (64%)	543 (60%)	580 (59%)	460 (51%)	417 (43%)
Liver retrieved (% offered)	300 (32%)	258 (26%)	287 (27%)	170 (29%)	313 (36%)	367 (40%)	408 (41%)	435 (49%)	544 (57%)
Livers transplanted overseas (% retrieved)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Livers transplanted in the UK (% retrieved)	198 (66%)	191 (74%)	176 (61%)	114 (67%)	195 (62%)	243 (66%)	262 (64%)	312 (72%)	370 (68%)
Liver not transplanted (% retrieved)	102 (16%)	67 (9%)	111 (14%)	56 (13%)	118 (21%)	124 (23%)	146 (25%)	123 (27%)	174 (42%)
Used for research (% not transplanted)	63 (62%)	39 (58%)	63 (57%)	23 (41%)	54 (46%)	57 (46%)	58 (40%)	52 (42%)	75 (43%)
2. SOLID ORGAN DONORS									
Number donors	616	643	655	388	623	653	732	724	794
Liver not offered for donation	44	49	35	26	36	30	28	45	52
Liver offered for donation	572	594	620	362	587	623	704	679	742
Liver not retrieved (% offered)	272 (48%)	336 (57%)	333 (54%)	192 (53%)	274 (47%)	256 (41%)	296 (42%)	244 (36%)	198 (27%)
Liver retrieved (% offered)	300 (52%)	258 (43%)	287 (46%)	170 (47%)	313 (53%)	367 (59%)	408 (58%)	435 (64%)	544 (73%)
Livers transplanted overseas (% retrieved)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Livers transplanted in the UK (% retrieved)	198 (66%)	191 (74%)	176 (61%)	114 (67%)	195 (62%)	243 (66%)	262 (64%)	312 (72%)	370 (68%)
Liver not transplanted (% retrieved)	102 (38%)	67 (20%)	111 (33%)	56 (29%)	118 (43%)	124 (48%)	146 (49%)	123 (50%)	174 (88%)
Used for research (% not transplanted)	63 (62%)	39 (58%)	63 (57%)	23 (41%)	54 (46%)	57 (46%)	58 (40%)	52 (42%)	75 (43%)

**Table 9A Reasons for non-offering of DBD livers (solid organ donors),
20 March 2017 to 19 March 2026, as at 23 April 2026**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
Family permission not sought	1 (1)	0 (0)	0 (0)	1 (1)	2 (2)	1 (0)	1 (0)	1 (1)	1 (1)
Family permission refused	20 (11)	10 (3)	8 (5)	3 (3)	6 (3)	2 (2)	9 (4)	6 (3)	7 (4)
Permission refused by coroner	18 (9)	7 (4)	0 (0)	4 (3)	7 (4)	6 (4)	5 (2)	4 (2)	3 (3)
Offer withdrawn	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Donor unsuitable - age	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Donor unsuitable - past history	30 (20)	17 (14)	19 (14)	18 (13)	18 (15)	14 (14)	19 (17)	14 (12)	14 (14)
Donor unstable	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Poor function	1 (0)	7 (6)	3 (3)	2 (2)	2 (2)	1 (1)	2 (2)	0 (0)	0 (0)
Donor unsuitable - virology	4 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Other, please specify	8 (1)	2 (1)	3 (0)	7 (1)	2 (1)	3 (3)	1 (1)	0 (0)	0 (0)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (3)	4 (4)
Not reported	21 (1)	28 (0)	35 (0)	45 (0)	41 (0)	32 (0)	28 (0)	27 (0)	30 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (0)
Total not offered	105 (45)	72 (28)	68 (22)	81 (23)	78 (27)	59 (24)	66 (26)	61 (24)	61 (26)

**Table 9B Reasons for non-retrieval of DBD livers (solid organ donors),
20 March 2017 to 19 March 2026, as at 23 April 2026**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
Donor unsuitable - cause of death	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)
Donor unsuitable - age	5 (3)	5 (4)	2 (2)	1 (0)	2 (0)	1 (0)	2 (0)	0 (0)	0 (0)
Donor unsuitable - past history	44 (21)	49 (25)	49 (29)	52 (30)	41 (21)	26 (19)	33 (18)	23 (15)	11 (4)
Donor unstable	2 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (0)	3 (0)	0 (0)	0 (0)
Donor unsuitable - size	1 (0)	9 (4)	3 (3)	2 (0)	3 (3)	1 (1)	4 (4)	2 (2)	3 (2)
Donor arrested	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	3 (0)	1 (0)	1 (0)
No suitable recipients	6 (4)	8 (4)	10 (5)	4 (2)	7 (3)	6 (6)	5 (5)	2 (2)	2 (1)
Centre already transplanting	1 (1)	0 (0)	0 (0)	1 (0)	0 (0)	1 (0)	1 (1)	0 (0)	0 (0)
Poor function	17 (11)	16 (12)	16 (9)	16 (8)	7 (6)	6 (3)	6 (5)	0 (0)	0 (0)
Infection	0 (0)	3 (0)	1 (0)	1 (0)	0 (0)	1 (0)	0 (0)	2 (1)	1 (0)
Donor unsuitable - Tumour, please specify	2 (0)	0 (0)	3 (0)	1 (0)	2 (0)	1 (0)	1 (0)	0 (0)	4 (1)
Anatomical anomaly, please specify	0 (0)	0 (0)	1 (1)	2 (1)	4 (3)	4 (4)	9 (7)	3 (0)	3 (3)
Other disease, please specify	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	2 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)
Contamination - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)
No beds	0 (0)	0 (0)	1 (1)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No response to fast track/group offer	1 (1)	2 (2)	1 (1)	1 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Steatosis (Fatty organ) - organ unsuitable	10 (8)	14 (12)	12 (10)	7 (5)	7 (7)	10 (8)	8 (6)	5 (4)	10 (8)
Donor unsuitable - virology	9 (0)	7 (1)	13 (3)	1 (0)	1 (0)	3 (1)	3 (1)	1 (0)	2 (1)
Organ/tissue unsuitable for transplant	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	3 (1)	2 (2)	0 (0)	0 (0)
Other, please specify	17 (8)	27 (14)	21 (10)	22 (4)	12 (2)	11 (7)	8 (3)	0 (0)	0 (0)
Fibrosis	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (0)	0 (0)	1 (1)
Prolonged time to asystole	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damage (retrieval injury), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Organ damage (pre-mortem), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	2 (0)	7 (6)	2 (2)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Organ failed viability assessment, please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Renal tumour, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	1 (0)	1 (0)
Other, please specify - centre reason	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	5 (4)	3 (2)
Total not retrieved	118 (60)	143 (80)	135 (76)	120 (55)	90 (48)	75 (50)	98 (56)	59 (40)	47 (28)

Table 9C Reasons DBD livers (solid organ donors) were retrieved but not transplanted, 20 March 2017 to 19 March 2026, as at 23 April 2026

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
Donor unsuitable - past history	0 (0)	0 (0)	1 (1)	6 (6)	3 (3)	5 (5)	7 (7)	0 (0)	6 (6)
Donor unsuitable - size	1 (1)	0 (0)	1 (1)	1 (1)	7 (7)	3 (3)	5 (5)	6 (6)	2 (2)
No suitable recipients	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Poor function	0 (0)	1 (1)	1 (1)	4 (4)	10 (10)	9 (9)	11 (11)	0 (0)	0 (0)
Infection	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Donor unsuitable - Tumour, please specify	3 (3)	0 (0)	2 (2)	0 (0)	2 (2)	2 (2)	2 (2)	0 (0)	1 (1)
Anatomical anomaly, please specify	3 (3)	4 (4)	3 (3)	10 (10)	20 (20)	9 (9)	20 (20)	11 (11)	8 (8)
Poor perfusion	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	2 (2)	1 (1)	3 (3)	1 (1)
Organ damaged	0 (0)	0 (0)	3 (3)	4 (4)	3 (3)	2 (2)	7 (7)	0 (0)	0 (0)
Ischaemia time too long - cold	4 (4)	4 (4)	3 (3)	5 (5)	4 (4)	1 (1)	2 (2)	3 (3)	2 (2)
Recipient unfit	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	3 (3)	0 (0)
Recipient died	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Recipient unavailable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Recipient refused	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)	0 (0)
No response to fast track/group offer	3 (3)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
Used for research after declined by centres	42 (42)	49 (49)	64 (64)	5 (5)	5 (5)	5 (5)	1 (1)	0 (0)	0 (0)
Steatosis (Fatty organ) - organ unsuitable	8 (8)	14 (14)	16 (16)	30 (30)	30 (30)	30 (30)	42 (42)	17 (17)	32 (32)
Organ/tissue unsuitable for transplant	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Other, please specify	11 (11)	19 (19)	32 (32)	24 (24)	18 (18)	22 (22)	11 (11)	0 (0)	0 (0)
Fibrosis	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)
Organ damage (retrieval injury), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)	3 (3)
Organ damage (at transplant centre), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Organ damage (pre-mortem), please specify	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Organ trauma - contusion, laceration	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)
Renal tumour, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Poor function following machine perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (6)	5 (5)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	3 (3)	0 (0)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (4)	6 (6)	10 (10)
Other - organ unsuitable for named recipient	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Other - recipient unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other, please specify - research/disposed of	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (7)	23 (23)	3 (3)
TOTAL RETRIEVED, NOT TRANSPLANTED	75 (75)	94 (94)	129 (129)	92 (92)	104 (104)	95 (95)	127 (127)	90 (90)	85 (85)

**Table 9D Reasons DCD livers (solid organ donors) were not offered,
20 March 2017 to 19 March 2026, as at 23 April 2026**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
Family permission not sought	2 (2)	2 (2)	1 (1)	0 (0)	1 (0)	2 (1)	2 (2)	3 (3)	3 (2)
Family permission refused	26 (6)	18 (6)	3 (1)	9 (2)	9 (4)	14 (3)	12 (0)	6 (0)	13 (5)
Permission refused by coroner	5 (0)	9 (5)	10 (3)	4 (3)	8 (4)	6 (3)	9 (4)	9 (4)	12 (4)
Offer withdrawn	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (0)
Donor unsuitable - age	8 (4)	4 (2)	9 (6)	23 (9)	2 (1)	2 (0)	5 (3)	1 (0)	3 (1)
Donor unsuitable - past history	51 (23)	52 (26)	42 (15)	25 (11)	34 (19)	35 (19)	34 (16)	44 (28)	48 (34)
Donor recovered	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Donor unstable	4 (1)	1 (1)	2 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Donor unsuitable - size	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Donor arrested	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	1 (0)
Poor function	13 (5)	15 (6)	8 (5)	1 (0)	9 (6)	5 (4)	6 (0)	0 (0)	0 (0)
Infection	4 (0)	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)
Other disease, please specify	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Donor unsuitable - virology	1 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other, please specify	26 (2)	17 (0)	23 (4)	4 (0)	12 (2)	3 (0)	4 (1)	0 (0)	0 (0)
Prolonged time to asystole	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	8 (5)	6 (5)
Not reported	72 (1)	98 (0)	122 (0)	65 (1)	87 (0)	81 (0)	75 (0)	90 (0)	84 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (0)
Other, please specify - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	1 (0)
Total not offered	212 (44)	220 (49)	220 (35)	131 (26)	162 (36)	149 (30)	151 (28)	170 (45)	177 (52)

**Table 9E Reasons for non-retrieval of DCD livers (solid organ donors),
20 March 2017 to 19 March 2026, as at 23 April 2026**

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
Donor unsuitable - cause of death	0 (0)	0 (0)	0 (0)	1 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Donor unsuitable - age	142 (55)	201 (94)	185 (82)	62 (30)	142 (71)	119 (70)	82 (39)	67 (40)	34 (24)
Donor unsuitable - past history	141 (75)	187 (99)	185 (93)	122 (66)	167 (98)	148 (87)	183 (105)	141 (97)	107 (67)
Donor recovered	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)
Donor unstable	2 (0)	3 (0)	0 (0)	0 (0)	1 (0)	5 (0)	2 (1)	0 (0)	0 (0)
Donor unsuitable - size	17 (12)	21 (15)	27 (19)	14 (8)	16 (10)	18 (15)	21 (15)	7 (5)	11 (6)
Donor arrested	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	2 (0)	0 (0)	4 (0)	1 (0)
No suitable recipients	26 (14)	30 (18)	41 (18)	25 (16)	24 (15)	14 (8)	37 (26)	22 (13)	14 (8)
No time	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Centre already transplanting	1 (1)	0 (0)	8 (5)	5 (2)	3 (1)	7 (4)	5 (2)	3 (2)	2 (2)
Poor function	49 (32)	49 (32)	51 (31)	30 (17)	32 (24)	28 (15)	45 (31)	0 (0)	0 (0)
Infection	2 (0)	3 (3)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	2 (1)	0 (0)
Donor unsuitable - Tumour	1 (0)	0 (0)	1 (0)	1 (0)	0 (0)	0 (0)	2 (0)	3 (1)	0 (0)
Anatomical anomaly	0 (0)	0 (0)	1 (1)	0 (0)	4 (4)	2 (2)	4 (4)	3 (2)	6 (4)
Poor perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)
Other disease, please specify	1 (1)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
HLA/ABO type	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	1 (1)	2 (1)	1 (1)	2 (2)	1 (1)	3 (3)	2 (2)	0 (0)	0 (0)
Contamination - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (0)
Ischaemia time too long - warm	0 (0)	1 (0)	2 (0)	13 (10)	22 (9)	32 (12)	30 (18)	13 (7)	18 (10)
Ischaemia time too long - cold	0 (0)	1 (0)	1 (1)	3 (3)	5 (3)	1 (0)	2 (2)	2 (2)	5 (2)
No beds	0 (0)	1 (1)	0 (0)	1 (0)	5 (3)	0 (0)	0 (0)	0 (0)	0 (0)
Transport difficulties	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
No response to fast track/group offer	11 (2)	4 (1)	5 (4)	11 (5)	3 (2)	1 (0)	3 (2)	3 (2)	1 (1)
Steatosis (Fatty organ)	12 (10)	7 (7)	9 (6)	1 (1)	2 (2)	11 (10)	6 (5)	8 (8)	10 (10)
Donor unsuitable - virology	8 (0)	10 (0)	13 (3)	4 (1)	6 (1)	0 (0)	3 (1)	3 (0)	3 (1)
Organ/tissue unsuitable for transplant	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)	3 (2)	0 (0)	0 (0)
Other, please specify	237 (69)	222 (64)	234 (69)	117 (28)	117 (24)	146 (28)	105 (27)	0 (0)	0 (0)
Fibrosis	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)	2 (1)
Prolonged time to asystole	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)	3 (0)	30 (3)	125 (24)	156 (30)
Organ damage (retrieval injury)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	2 (2)
Organ damage (pre-mortem)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Poor function - initial assessment	0 (0)	1 (1)	1 (0)	0 (0)	1 (1)	0 (0)	7 (6)	20 (15)	16 (13)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	8 (8)	6 (6)
No suitable recipients due to reduced patient list	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Other, please specify - donor unsuitable	0 (0)	0 (0)	2 (0)	1 (1)	0 (0)	0 (0)	2 (0)	7 (2)	8 (1)
Other, please specify - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	6 (5)	3 (3)
Other, please specify - centre reason	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Other, please specify - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	6 (6)	8 (6)
Other - recipient unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
TOTAL NOT RETRIEVED	652 (272)	746 (336)	768 (333)	416 (192)	558 (274)	543 (256)	580 (296)	460 (244)	417 (198)

Table 9F Reasons DCD livers (solid organ donors) retrieved but not transplanted, 20 March 2017 to 19 March 2026, as at 23 April 2026

	17/18	18/19	19/20	20/21	21/22	22/23	23/24	24/25	25/26
REASONS RETRIEVED BUT NOT TRANSPLANTED									
Donor unsuitable - age	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	6 (6)	2 (2)	0 (0)	4 (4)
Donor unsuitable - past history	0 (0)	1 (1)	2 (2)	2 (2)	4 (4)	0 (0)	6 (6)	1 (1)	0 (0)
Donor unsuitable - size	0 (0)	1 (1)	1 (1)	3 (3)	6 (6)	4 (4)	12 (12)	7 (7)	4 (4)
No suitable recipients	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Poor function	0 (0)	0 (0)	1 (1)	5 (5)	15 (15)	19 (19)	22 (22)	0 (0)	0 (0)
Infection	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)	1 (1)	0 (0)
Donor unsuitable - Tumour	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	3 (3)
Anatomical anomaly	1 (1)	0 (0)	5 (5)	6 (6)	10 (10)	11 (11)	14 (14)	12 (12)	15 (15)
Poor perfusion	2 (2)	2 (2)	2 (2)	1 (1)	2 (2)	1 (1)	5 (5)	6 (6)	12 (12)
HLA/ABO type	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Organ damaged	1 (1)	0 (0)	3 (3)	2 (2)	3 (3)	6 (6)	5 (5)	0 (0)	0 (0)
Contamination - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
Ischaemia time too long - warm	4 (4)	3 (3)	3 (3)	4 (4)	6 (6)	3 (3)	12 (12)	3 (3)	6 (6)
Ischaemia time too long - cold	3 (3)	6 (6)	4 (4)	2 (2)	7 (7)	5 (5)	10 (10)	3 (3)	7 (7)
Recipient unfit	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Recipient died	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Recipient unavailable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Taken for hepatocytes	0 (0)	0 (0)	2 (2)	2 (2)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
No response to fast track/group offer	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Used for research after declined by centres	60 (60)	36 (36)	57 (57)	5 (5)	7 (7)	2 (2)	2 (2)	0 (0)	0 (0)
Steatosis (Fatty organ) - organ unsuitable	7 (7)	5 (5)	5 (5)	4 (4)	22 (22)	33 (33)	14 (14)	28 (28)	48 (48)
Organ/tissue unsuitable for transplant	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)
Other, please specify	22 (22)	12 (12)	25 (25)	18 (18)	32 (32)	29 (29)	21 (21)	0 (0)	0 (0)
Fibrosis	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	3 (3)	2 (2)
Organ damage (retrieval injury)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	11 (11)
Organ damage (at transplant centre)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Organ damage (pre-mortem)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Poor function - initial assessment	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (6)
Poor function at retrieval	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (7)	4 (4)
Renal tumour - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	0 (0)
Poor function after machine perfusion	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	15 (15)	25 (25)
Other - donor unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other - logistic issues	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Other - centre reason	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Other - organ unsuitable	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	9 (9)	14 (14)
Other - organ unsuitable for named recipient	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Other - research/disposed of	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	15 (15)	11 (11)
TOTAL RETRIEVED, NOT TRANSPLANTED	102 (102)	67 (67)	111 (111)	56 (56)	118 (118)	124 (124)	146 (146)	123 (123)	174 (174)

3.4.3. **Figure 8** shows the DBD liver offering outcome for all livers offered regardless of whether any solid organs were retrieved for the purposes of transplantation. **Figure 8** shows that 276 livers were offered during the first quarter of NLOS which was the second highest number of livers offered during the 96 month period.

3.4.4. The percentage of organs retrieved and transplanted per quarter ranged from 77% to 82% in the year prior and 67% to 83% in the 96 months post the introduction of NLOS. The percentage of livers retrieved and used for research ranged between 3% and 6% in the year prior and 1% to 10% for the 96 months post the introduction of NLOS.

3.4.5. **Figure 8A** shows the equivalent information for all solid organ donors where the liver was offered for transplantation and at least one organ (not necessarily the liver) was retrieved for the purposes of transplantation.





Figure 8A DBD donor liver offering outcome for solid organ donors, by quarter and offering outcome, 20 March 2017 to 19 March 2026



- 3.4.6. **Figure 9a** show the number of livers offered during the first 96 months of the new scheme at each stage of the liver offering pathway up to and including the liver and cardiothoracic section. Livers offered during COVID are included in **Figure 9a** but excluded at the elective stage of **Figure 9b**. 78 of the 6465 donors did not meet the DBD criteria at the start of the offering process. Fifty-one of the 78 were only ever offered as DCD and 45 were retrieved and transplanted. These livers are hence excluded from the offering pathway.
- 3.4.7. Livers from 765 donors meeting the DBD criteria were accepted and transplanted into super-urgent patients (including 29 super-urgent patients in Dublin). 1620 livers were offered to hepatoblastoma/prioritised paediatric/ACLF patients and 193 were accepted and transplanted. 621 livers were offered to the liver and intestinal list and 58 were accepted and transplanted. Please note that a liver accepted and used at any stage may have been provisionally offered on to elective patients or fast-tracked before being accepted and used. These have not been included in the number of livers offered in later stages along with livers that may have been accepted, split and transplanted into two patients.
- 3.4.8. 1131 livers were offered to liver and cardiothoracic patients and ten were accepted and transplanted combined liver and cardiothoracic patients. It should be noted that offers may be made when the cardiothoracic organs are unavailable.

- 3.4.9. **Figure 9b** shows the number of livers that were offered to elective patients and hadn't been accepted and used for super-urgent, hepatoblastoma, liver/intestinal and liver/cardiothoracic patients. Of the 5383 livers offered to elective patients, 5304 were adult donors and 79 were paediatric donors (aged less than 16 years or weighing 40 kg or less). 929 adult donors met the split criteria and 866 livers were offered to paediatric centres for paediatric/small adult patients. 282 of the 866 livers were accepted and transplanted. Sixty livers were only offered to paediatric patients and not offered to elective adult patient or fast-tracked.
- 3.4.10. 164 livers were offered to elective patients between 27 March and 9 July 2020.
- 3.4.11. Ninety percent of livers offered to elective patients were randomly allocated to the elective CLD/HCC pathway while ten percent were allocated to the variant syndrome pathway. 4196 were offered to named CLD/HCC patients and 2516 (54%) were accepted and transplanted. 438 were offered to the VS pathway and 219 (50%) were accepted and transplanted.

Figure 9A Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 March 2026







Figure 9B Liver offering flow chart for UK DBD donors offered between 20 March 2018 and 19 March 2026



3.4.12. **Table 10** shows the number of liver offers made to each UK liver transplant centre in either the twelve months prior to the new scheme or during the first 96 months of the new scheme. Livers offered to intestinal or liver/cardiothoracic patients have been excluded. The number of offers made to UK liver transplant centres has increased compared with the 12 months prior.

Table 10 Number of DBD liver only offers (excludes intestinal and liver/cardiothoracic offers) per UK transplant centre, 20 March 2017 to 19 March 2026									
Period		Newcastle	Leeds	Cambridge	Royal Free	Kings College	Birmingham	Edinburgh	Total
2017/2018	No. offers (no. donors)	344 (323)	501 (435)	348 (323)	384 (352)	516 (455)	495 (417)	374 (351)	2962 (944)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	2 (1, 5)
2018/2019	No. offers (no. donors)	431 (378)	645 (481)	480 (391)	566 (459)	1019 (638)	867 (582)	511 (426)	4519 (982)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	3 (2, 7)
2019/2020	No. offers (no. donors)	433 (387)	735 (546)	455 (386)	490 (421)	903 (630)	830 (592)	471 (416)	4317 (987)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	3 (1, 7)
2020/2021	No. offers (no. donors)	404 (345)	635 (446)	436 (354)	467 (371)	813 (534)	674 (469)	513 (398)	3942 (781)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	4 (1, 8)
2021/2022	No. offers (no. donors)	316 (286)	613 (446)	403 (349)	482 (377)	924 (566)	731 (488)	407 (346)	3876 (787)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	4 (1, 8)
20 Mar – 3 Oct 22	No. offers (no. donors)	162 (141)	303 (228)	212 (187)	195 (152)	417 (262)	382 (253)	203 (175)	1874 (415)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	3 (1, 7)
4 Oct 22 – 3 Oct 23	No. offers (no. donors)	284 (259)	578 (424)	359 (300)	384 (326)	1244 (604)	747 (467)	375 (327)	3971 (765)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	2 (1, 3)	1 (1, 2)	1 (1, 1)	4 (2, 8)
4 Oct 23 – 3 Oct 24	No. offers (no. donors)	292 (259)	577 (422)	407 (330)	396 (325)	779 (498)	693 (447)	400 (336)	3544 (731)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	4 (2, 8)
4 Oct 24 – 3 Oct 25	No. offers (no. donors)	204 (190)	540 (374)	276 (241)	286 (246)	571 (412)	534 (354)	353 (297)	2764 (646)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 2)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	3 (2, 7)
4 Oct 25 – 19 Mar 26	No. offers (no. donors)	68 (63)	192 (150)	125 (110)	105 (95)	251 (179)	231 (157)	148 (127)	1120 (284)
	Median (IQR) offers per donor	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 1)	1 (1, 2)	1 (1, 2)	1 (1, 1)	3 (1, 6)

3.4.13. **Figure 10** shows, for livers that were ultimately transplanted, the outcome of liver offers made in either the last year prior to the new scheme or during the first 96 months of the new scheme. The last time periods have been split as the parameter estimates and baseline survivor functions were updated on 4 October 2022. Fast-track offers that were not accepted and transplanted (i.e. declined or accepted and not used fast-track offers) as well as livers offered from either DCD or positive virology donors were excluded. It should be noted that offers of left and right lobes are included. The proportion of offers accepted and not used has increased compared with the 12 months prior. **Figure 10A** shows the equivalent for each transplant centre.



- 3.4.14. 10356 (31%) of the 32889 offers made in the first 96 months post NLOS were to named recipients. All offers between 27 March and 9 July 2020 are excluded as centres were offered livers for any clinically urgent patient rather than named patients. 7097 of the named patient offers involved livers that were ultimately retrieved and transplanted.
- 3.4.15. The number of named patient offers per donor ranged between 1 and 18 with a median of two named patient offers per donor. The number of named offers per patient ranged between 1 and 34 with a median of two offers per patient.
- 3.4.16. Seventy three patients at 7 centres were offered 11 or more livers in the 96 month time period (19 were offered 11 livers, 18 were offered 12 livers, 12 were offered 13 livers, 9 were offered 14 livers, 3 were offered 15 livers, 1 was offered 16, 2 were offered 17, 3 were offered 18 livers, 1 was offered 19 livers, 1 was offered 21, 2 were offered 27, 1 was offered 29 and 1 was offered 34 livers). Ten of the 73 patients offered 11 or more livers in the 96 month time period were on the variant syndrome pathway, 4 were on the HCC pathway and 59 were on the CLD pathway.
- 3.4.17. **Table 11** shows the outcome of named patient liver offers made during the first 96 months of the new scheme by type of patient. It also shows the offer outcome after excluding named patients offers for livers that were ultimately not transplanted. Overall, forty-seven percent of named patient offers were accepted and 27% were accepted and transplanted. The number of transplants will not agree with the flow chart in **Figure 9A** as **Table 11** includes all elective named patient offers and will include livers that were offered as a right lobe after being accepted for super-urgent and hepatoblastoma patients.
- 3.4.18. **Figures 11A, 11B and 11C** shows the outcome of named CLD patient liver offers made during the first 96 months of the new scheme for livers ultimately transplanted by aetiology, transplant centre and blood group respectively. There were statistically significant differences at a 5% significance level in the outcomes for patients with ALD ($p=0.003$), AID ($p=0.04$) and retransplant ($p=0.02$). Although the number of offers has decreased for patients with other disease group, there was no evidence of a statistically significant difference in outcomes ($p=0.74$).
- 3.4.19. **Figures 12A and 12B** for shows the outcome of named HCC patient liver offers made during the first 96 months of the new scheme for livers ultimately transplanted by transplant centre and blood group respectively. **Figures 13A and 13B** show equivalent information for variant syndrome patients.

Table 11 Offer outcome for named elective patient offers made between 20 March 2018 and 19 March 2026 (excluding 27 March 2020 to 9 July 2020), by type of patient									
Type of patient	Disease group	Offer outcome for all named patient offers				Offer outcome for all named patient offers for livers that were ultimately transplanted			
		Declined	Accepted but not used	Transplanted	Total	Declined	Accepted but not used	Transplanted	Total
Chronic Liver Disease (CLD)	2018/2019	789 (55)	246 (17)	409 (28)	1444	491 (47)	142 (14)	409 (39)	1042
	2019/2020	617 (50)	250 (20)	361 (29)	1228	346 (42)	118 (14)	361 (44)	825
	2020/2021 ¹	553 (59)	162 (17)	223 (24)	938	315 (51)	78 (13)	223 (36)	616
	2021/2022	802 (58)	252 (18)	336 (24)	1390	493 (51)	131 (14)	336 (35)	960
	20 Mar – 3 Oct 22	290 (51)	110 (19)	169 (30)	569	202 (47)	57 (13)	169 (39)	428
	4 Oct 22 – 3 Oct 23	511 (52)	194 (20)	286 (29)	991	267 (42)	89 (14)	286 (45)	642
	4 Oct 23 – 3 Oct 24	502 (52)	221 (23)	250 (26)	973	288 (45)	99 (16)	250 (39)	637
	4 Oct 24 – 3 Oct 25	368 (44)	208 (25)	253 (31)	829	210 (38)	91 (16)	253 (46)	554
	4 Oct 25 – 19 Mar 26	140 (43)	77 (24)	108 (33)	325	93 (38)	46 (19)	108 (44)	247
	Total	4572 (53)	1720 (20)	2395 (28)	8687	2705 (45)	851 (14)	2395 (40)	5951
HCC	2018/2019	31 (53)	12 (20)	16 (27)	59	24 (53)	5 (11)	16 (36)	45
	2019/2020	29 (44)	12 (18)	25 (38)	66	11 (24)	9 (20)	25 (56)	45
	2020/2021 ¹	31 (57)	13 (24)	10 (19)	54	25 (61)	6 (15)	10 (24)	41
	2021/2022	40 (59)	11 (16)	17 (25)	68	17 (44)	5 (13)	17 (44)	39
	20 Mar – 3 Oct 22	27 (60)	8 (18)	10 (22)	45	22 (61)	4 (11)	10 (28)	36
	4 Oct 22 – 3 Oct 23	59 (53)	26 (23)	26 (23)	111	24 (43)	6 (11)	26 (46)	56
	4 Oct 23 – 3 Oct 24	49 (46)	29 (27)	29 (27)	107	25 (40)	8 (13)	29 (47)	62
	4 Oct 24 – 3 Oct 25	23 (39)	17 (29)	19 (32)	59	10 (26)	9 (24)	19 (50)	38
	4 Oct 25 – 19 Mar 26	6 (22)	8 (30)	13 (48)	27	4 (18)	5 (23)	13 (59)	22
	Total	295 (49)	136 (23)	165 (28)	596	162 (42)	57 (15)	165 (43)	384
Variant syndrome	2018/2019	80 (56)	27 (19)	35 (25)	142	55 (53)	14 (13)	35 (34)	104
	2019/2020	92 (58)	28 (18)	39 (25)	159	66 (55)	16 (13)	39 (32)	121
	2020/2021 ¹	58 (64)	19 (21)	13 (14)	90	22 (50)	9 (20)	13 (30)	44
	2021/2022	132 (68)	38 (19)	25 (13)	195	94 (65)	26 (18)	25 (17)	145
	20 Mar – 3 Oct 22	49 (65)	13 (17)	13 (17)	75	30 (60)	7 (14)	13 (26)	50
	4 Oct 22 – 3 Oct 23	68 (63)	16 (15)	24 (22)	108	43 (59)	6 (8)	24 (33)	73
	4 Oct 23 – 3 Oct 24	93 (60)	30 (19)	33 (21)	156	61 (53)	21 (18)	33 (29)	115
	4 Oct 24 – 3 Oct 25	66 (60)	17 (15)	27 (25)	110	43 (52)	13 (16)	27 (33)	83
	4 Oct 25 – 19 Mar 26	15 (39)	12 (32)	11 (29)	38	10 (37)	6 (22)	11 (41)	27
	Total	653 (61)	200 (19)	220 (21)	1073	424 (56)	118 (15)	220 (29)	762
Total named patient offers		5520 (53)	2056 (20)	2780 (27)	10356	3291 (46)	1026 (14)	2780 (39)	7097

¹ Offers between 27 March 2020 and 9 July excluded

Figure 11A Named CLD patient offer outcome, by year and disease group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)




Figure 11B Named CLD patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)




Figure 11C Named CLD patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)




Figure 12A Named HCC patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)




Figure 12B Named HCC patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)




Figure 13A Named VS patient offer outcome, by year and transplant centre, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)





Figure 13B Named VS patient offer outcome, by year and blood group, for DBD livers that were offered and ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding offers between 27 March and 9 July 2020)



- 3.4.20. **Table 12A, 12B, 12C** and **Figures 14A, 14B** and **14C** show the median Transplant Benefit Score (TBS) at time of offer for named elective patient offers for *livers ultimately transplanted* by, separately, aetiology, centre and blood group. Overall, the median TBS for CLD ranged between 1123 and 1227 days by year for the original NLOS.
- 3.4.21. **Table 13** shows the median Transplant Benefit Score (TBS) at time of offer for named elective HCC patient offers for *livers ultimately transplanted* by UKELD group.

Table 12A Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by disease group, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020)

		2018/19	2019/20	2020/21	2021/22	20 March – 3 Oct 2022	4 Oct 22 – 3 Oct 23	4 Oct 23 – 3 Oct 24	4 Oct 24 – 3 Oct 25	4 Oct 25 – 19 Mar 26
Disease group										
HCC	N	45	45	41	39	36	56	62	38	22
	Median (IQR)	1106 (676 - 1315)	980 (775 - 1089)	463 (192 - 973)	938 (543 - 1152)	1276 (1137 - 1417)	1079 (894 - 1195)	1022 (870 - 1167)	1178 (1013 - 1231)	869 (752 - 1022)
Hepatitis C	N	33	19	17	24	13	9	13	5	2
	Median (IQR)	1057 (920 - 1251)	1170 (926 - 1392)	1107 (994 - 1304)	1239 (1056 - 1376)	1185 (1097 - 1288)	1177 (1097 - 1199)	1122 (963 - 1265)	990 (940 - 1174)	1397 (1273 - 1521)
ALD	N	280	264	192	315	110	245	216	190	88
	Median (IQR)	1246 (1032 - 1351)	1230 (1080 - 1353)	1185 (982 - 1307)	1212 (1026 - 1348)	1236 (1103 - 1367)	1226 (1087 - 1382)	1208 (1028 - 1400)	1244 (1079 - 1407)	1223 (1104 - 1398)
Hepatitis B	N	18	6	7	14	2	15	0	14	1
	Median (IQR)	1062 (971 - 1380)	1182 (998 - 1406)	1370 (1261 - 1555)	971 (833 - 1221)	1216 (1165 - 1267)	1132 (988 - 1238)	-	1113 (1001 - 1247)	1228 (1228 - 1228)
PSC	N	105	98	83	126	56	95	98	72	25
	Median (IQR)	1199 (1017 - 1316)	1179 (1092 - 1281)	1084 (838 - 1221)	1167 (968 - 1258)	1187 (989 - 1303)	1078 (909 - 1239)	1123 (1005 - 1295)	1144 (1029 - 1236)	1117 (1017 - 1304)
PBC	N	86	56	74	75	48	45	51	42	15
	Median (IQR)	1081 (1007 - 1223)	1089 (1015 - 1212)	1091 (949 - 1256)	1037 (870 - 1227)	1237 (1081 - 1262)	1108 (998 - 1209)	971 (876 - 1185)	1073 (979 - 1218)	1119 (943 - 1210)
AID	N	130	69	42	80	30	39	20	27	18
	Median (IQR)	1263 (1109 - 1379)	1202 (1005 - 1332)	1284 (1202 - 1354)	1215 (994 - 1432)	1290 (1234 - 1442)	1314 (1158 - 1450)	1137 (951 - 1362)	1388 (1264 - 1519)	1053 (862 - 1280)
Metabolic	N	200	176	104	190	100	104	103	78	31
	Median (IQR)	1215 (1050 - 1326)	1169 (1041 - 1310)	1157 (1032 - 1265)	1243 (1082 - 1350)	1258 (1168 - 1338)	1083 (955 - 1192)	1106 (1013 - 1210)	1113 (1006 - 1239)	1057 (902 - 1210)
Other	N	28	26	28	36	21	7	15	11	10
	Median (IQR)	992 (797 - 1080)	996 (939 - 1163)	1042 (708 - 1168)	1062 (885 - 1246)	1176 (1149 - 1203)	1045 (223 - 1094)	1179 (626 - 1236)	1163 (1111 - 1196)	965 (894 - 1131)
Retransplant	N	162	111	69	100	48	83	121	115	57
	Median (IQR)	1117 (1011 - 1236)	1074 (984 - 1199)	1011 (879 - 1122)	1103 (921 - 1238)	1154 (1087 - 1205)	1098 (1004 - 1210)	1060 (951 - 1164)	1120 (1030 - 1261)	1082 (911 - 1251)
Overall CLD	N	1042	825	616	960	428	642	637	554	247
	Median (IQR)	1178 (1017 - 1314)	1169 (1031 - 1303)	1124 (966 - 1274)	1179 (988 - 1304)	1227 (1121 - 1319)	1146 (1018 - 1303)	1123 (985 - 1278)	1159 (1037 - 1310)	1142 (976 - 1293)

Table 12B Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by type of patient and centre, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020)

		2018/19	2019/20	2020/21	2021/22	20 March – 3 Oct 2022	4 Oct 22 – 3 Oct 23	4 Oct 23 – 3 Oct 24	4 Oct 24 – 3 Oct 25	4 Oct 25 – 19 Mar 26
HCC										
Newcastle	N	0	2	5	4	0	1	1	0	0
	Median (IQR)	-	1161 (1034 - 1289)	-14 (-55 - 570)	564 (254 - 697)	-	1314 (1314 - 1314)	1244 (1244 - 1244)	-	-
Leeds	N	1	16	10	6	20	17	15	11	7
	Median (IQR)	668 (668 - 668)	971 (901 - 1090)	484 (-6 - 854)	993 (968 - 1036)	1179 (1129 - 1410)	1126 (1025 - 1249)	956 (857 - 1149)	1091 (938 - 1179)	896 (752 - 1147)
Cambridge	N	10	2	6	4	3	9	11	2	4
	Median (IQR)	1322 (1265 - 1458)	867 (297 - 1437)	292 (65 - 625)	1196 (553 - 1254)	1518 (1212 - 1530)	884 (858 - 899)	915 (881 - 1049)	918 (751 - 1086)	839 (561 - 948)
Royal Free	N	9	7	0	3	0	1	2	1	0
	Median (IQR)	1313 (676 - 1409)	507 (242 - 943)	-	1116 (643 - 1152)	-	1405 (1405 - 1405)	1249 (1221 - 1278)	1180 (1180 - 1180)	-
Kings College	N	7	8	7	13	3	11	16	11	2
	Median (IQR)	598 (515 - 1104)	1060 (1051 - 1105)	463 (415 - 1318)	1075 (910 - 1371)	1190 (1000 - 1339)	1194 (1121 - 1262)	1081 (937 - 1194)	1190 (980 - 1265)	553 (176 - 930)
Birmingham	N	9	6	5	5	3	11	6	3	6
	Median (IQR)	1026 (642 - 1179)	923 (549 - 1062)	1090 (1051 - 1103)	448 (-103 - 582)	1203 (766 - 1365)	1012 (925 - 1080)	768 (507 - 1113)	1178 (1076 - 1437)	860 (817 - 946)
Edinburgh	N	9	4	8	4	7	6	11	10	3
	Median (IQR)	1081 (1052 - 1120)	784 (470 - 1020)	339 (236 - 831)	651 (331 - 1063)	1405 (1359 - 1424)	716 (670 - 948)	1026 (982 - 1147)	1197 (1178 - 1270)	1022 (397 - 1041)
CLD										
Newcastle	N	82	65	51	65	21	17	31	22	7
	Median (IQR)	1255 (1085 - 1340)	1128 (1064 - 1280)	1068 (952 - 1264)	1259 (1184 - 1352)	1169 (983 - 1257)	1236 (1055 - 1346)	1105 (957 - 1224)	1120 (967 - 1201)	1017 (878 - 1250)
Leeds	N	103	99	94	129	65	115	120	110	26
	Median (IQR)	1097 (923 - 1289)	1183 (1031 - 1309)	1094 (932 - 1235)	1186 (1064 - 1288)	1250 (1158 - 1353)	1164 (1072 - 1255)	1174 (1049 - 1255)	1161 (1077 - 1364)	1088 (945 - 1296)
Cambridge	N	106	112	77	122	60	91	73	59	30
	Median (IQR)	1205 (997 - 1306)	1223 (1084 - 1310)	1122 (1011 - 1224)	1158 (978 - 1313)	1260 (1177 - 1332)	1121 (1041 - 1303)	1120 (1004 - 1301)	1215 (1038 - 1336)	1132 (1015 - 1262)
Royal Free	N	166	109	92	121	50	70	72	55	22
	Median (IQR)	1190 (996 - 1342)	1154 (1037 - 1255)	1102 (930 - 1276)	1176 (1027 - 1308)	1183 (1153 - 1319)	1154 (954 - 1316)	1204 (1005 - 1375)	1213 (1105 - 1296)	1226 (1069 - 1341)
Kings College	N	241	192	116	208	76	129	116	110	64
	Median (IQR)	1169 (1025 - 1310)	1147 (1006 - 1336)	1165 (1011 - 1254)	1153 (965 - 1266)	1206 (1089 - 1272)	1165 (1029 - 1305)	1108 (968 - 1244)	1119 (980 - 1285)	1069 (891 - 1261)
Birmingham	N	224	172	85	202	86	129	127	102	47
	Median (IQR)	1198 (1057 - 1318)	1153 (1016 - 1297)	1162 (917 - 1350)	1127 (958 - 1300)	1172 (1054 - 1303)	1132 (992 - 1284)	1048 (948 - 1248)	1147 (1035 - 1289)	1251 (960 - 1365)
Edinburgh	N	120	76	101	113	70	91	98	96	51
	Median (IQR)	1132 (1008 - 1283)	1175 (1041 - 1315)	1147 (1032 - 1270)	1258 (1120 - 1345)	1253 (1175 - 1328)	1124 (998 - 1323)	1103 (975 - 1358)	1186 (1054 - 1325)	1155 (1075 - 1255)

Table 12C Median (IQR) Transplant Benefit Score (TBS) for named elective patient offers for livers ultimately transplanted, by type of patient and centre, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020)

		2018/19	2019/20	2020/21	2021/22	20 March – 3 Oct 2022	4 Oct 22 – 3 Oct 23	4 Oct 23 – 3 Oct 24	4 Oct 24 – 3 Oct 25	4 Oct 25 – 19 Mar 26
HCC										
O	N	19	13	8	6	17	12	27	14	5
	Median (IQR)	1285 (1105 - 1381)	1062 (474 - 1164)	914 (704 - 1305)	1134 (904 - 1187)	1385 (1339 - 1425)	1122 (1021 - 1178)	1120 (1026 - 1181)	1081 (1013 - 1180)	1041 (1022 - 1147)
A	N	17	21	23	28	14	33	27	15	12
	Median (IQR)	1256 (855 - 1329)	1034 (920 - 1164)	402 (65 - 915)	953 (646 - 1196)	1144 (1025 - 1186)	1076 (890 - 1249)	959 (851 - 1042)	1203 (1179 - 1268)	834 (777 - 952)
B	N	4	4	5	1	4	11	5	5	3
	Median (IQR)	672 (629 - 698)	958 (851 - 990)	355 (192 - 1028)	943 (943 - 943)	1485 (1415 - 1524)	1068 (858 - 1195)	953 (914 - 1235)	980 (695 - 1130)	896 (869 - 930)
AB	N	5	7	5	4	1	0	3	4	2
	Median (IQR)	545 (515 - 598)	549 (348 - 899)	276 (-55 - 415)	373 (144 - 515)	232 (232 - 232)	-	738 (406 - 834)	678 (542 - 1008)	356 (314 - 397)
CLD										
O	N	460	360	246	379	176	289	288	210	86
	Median (IQR)	1189 (1057 - 1331)	1234 (1113 - 1346)	1210 (1071 - 1306)	1253 (1152 - 1346)	1268 (1217 - 1349)	1188 (1094 - 1345)	1198 (1053 - 1336)	1239 (1140 - 1364)	1263 (1155 - 1371)
A	N	429	343	269	438	188	240	283	239	113
	Median (IQR)	1190 (997 - 1313)	1082 (976 - 1233)	1068 (907 - 1211)	1081 (919 - 1259)	1164 (1051 - 1256)	1102 (976 - 1277)	1059 (938 - 1185)	1117 (1014 - 1258)	1079 (916 - 1197)
B	N	88	71	74	106	46	75	45	63	26
	Median (IQR)	1140 (963 - 1291)	1193 (1061 - 1285)	1107 (972 - 1344)	1190 (971 - 1293)	1182 (1057 - 1299)	1066 (947 - 1239)	1210 (1044 - 1308)	1105 (885 - 1358)	1000 (966 - 1284)
AB	N	65	51	27	37	18	38	21	39	22
	Median (IQR)	978 (640 - 1269)	1046 (876 - 1363)	1045 (765 - 1126)	813 (460 - 1137)	1188 (906 - 1284)	1074 (853 - 1148)	890 (709 - 990)	943 (777 - 1193)	891 (604 - 1234)

Table 13 Median (IQR) Transplant Benefit Score (TBS) for named elective HCC patient offers for livers ultimately transplanted, by UKELD score group, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020)

		2018/19	2019/20	2020/21	2021/22	20 March – 3 Oct 2022	4 Oct 22 – 3 Oct 23	4 Oct 23 – 3 Oct 24	4 Oct 24 – 3 Oct 25	4 Oct 25 – 19 Mar 26
<49	N	1	9	15	4	1	7	11	2	3
	Median (IQR)	591 (591 - 591)	297 (182 - 507)	70 (-6 - 415)	9 (-57 - 163)	232 (232 - 232)	758 (670 - 884)	858 (584 - 915)	808 (636 - 980)	397 (176 - 719)
49-53	N	8	9	12	13	1	27	25	12	12
	Median (IQR)	607 (497 - 695)	916 (810 - 980)	690 (232 - 1070)	643 (448 - 1036)	766 (766 - 766)	1068 (939 - 1139)	956 (859 - 1167)	1049 (723 - 1147)	869 (813 - 992)
≥ 54	N	36	27	14	22	34	22	26	24	7
	Median (IQR)	1261 (1059 - 1358)	1054 (943 - 1227)	914 (767 - 1289)	1029 (910 - 1254)	1343 (1159 - 1424)	1145 (1079 - 1305)	1108 (1042 - 1192)	1191 (1127 - 1265)	930 (802 - 1041)

Figure 14A Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020), by aetiology




Figure 14B Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020), by transplant centre





Figure 14C Median Transplant Benefit Score (TBS) for named elective chronic liver disease patient offers for livers ultimately transplanted, 20 March 2018 to 19 March 2026 (excluding 27 March 2020 to 9 July 2020), by blood group



3.5. TRANSPLANT ACTIVITY


3.5.1. **Table 14** shows the urgency status and age group of DBD and DCD liver transplants performed in the UK between 20 March 2017 and 19 March 2026. The proportion of super-urgent transplants performed has increased from prior to NLOS implementation to 2022/23 (11% vs 14% respectively). In years since 2022/23, the proportion of super-urgent transplants performed has been similar to the year prior to NLOS (11% in 2017/18) and, more recently, between 20 March 2025 and 19 March 2026, 8% of transplants were super-urgent. There was no evidence of a statistically significant difference in proportion of super-urgent transplants between years for adult DBD liver and adult liver/kidney transplants (overall Chi-squared p-value=0.11) or for paediatric transplants (overall Chi-squared p-value=0.06). Highlighted in red are the transplants that will be analysed further in the rest of the section.

Table 14 Urgency status and age group for deceased donor liver transplants performed in the UK, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)	2023/24 N (%)	2024/25 N (%)	2025/26 N (%)
DBD liver									
Adult elective liver and liver/kidney	640 (78.1)	623 (77.6)	608 (77.8)	477 (76.8)	481 (74.6)	449 (70.7)	452 (75.3)	415 (73.6)	407 (75.0)
Adult elective liver/cardiothoracic	2 (0.2)	0 (0)	2 (0.3)	3 (0.5)	3 (0.5)	1 (0.2)	0 (0)	0 (0)	1 (0.2)
Adult elective multivisceral	6 (0.7)	5 (0.6)	6 (0.8)	1 (0.2)	9 (1.4)	8 (1.3)	4 (0.7)	5 (0.9)	3 (0.6)
Adult super-urgent liver and liver/kidney	94 (11.5)	100 (12.5)	83 (10.6)	61 (9.8)	75 (11.6)	96 (15.1)	77 (12.8)	75 (13.3)	67 (12.3)
Adult super-urgent multivisceral	1 (0.1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	0 (0)
Paediatric elective liver and liver/kidney	57 (7.0)	55 (6.8)	64 (8.2)	63 (10.1)	53 (8.2)	53 (8.3)	48 (8)	51 (9.0)	58 (10.7)
Paediatric elective multivisceral	6 (0.7)	3 (0.4)	2 (0.3)	4 (0.6)	2 (0.3)	3 (0.5)	3 (0.5)	3 (0.5)	1 (0.2)
Paediatric super-urgent liver and liver/kidney	13 (1.6)	17 (2.1)	16 (2.0)	12 (1.9)	22 (3.4)	24 (3.8)	16 (2.7)	15 (2.7)	6 (1.1)
Total UK DBD transplants	819 (100)	803 (100)	781 (100)	621 (100)	645 (100)	635 (100)	600 (100)	564 (100)	543 (100)
DCD liver									
Adult elective liver and liver/kidney	190 (96)	185 (96.9)	173 (97.7)	110 (95.7)	189 (97.9)	243 (97.6)	257 (97.3)	310 (98.4)	367 (98.4)
Adult elective liver/cardiothoracic	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)
Adult super-urgent liver and liver/kidney	1 (0.5)	1 (0.5)	3 (1.7)	2 (1.7)	2 (1.0)	1 (0.4)	2 (0.8)	1 (0.3)	3 (0.8)
Paediatric elective liver and liver/kidney	7 (3.5)	4 (2.1)	1 (0.6)	2 (1.7)	2 (1.0)	5 (2.0)	4 (1.5)	3 (1.0)	3 (0.8)
Paediatric super-urgent liver and liver/kidney	0 (0)	1 (0.5)	0 (0)	1 (0.9)	0 (0)	0 (0)	0 (0)	1 (0.3)	0 (0)
Total UK DCD transplants	198 (100)	191 (100)	177 (100)	115 (100)	193 (100)	249 (100)	264 (100)	315 (100)	373 (100)
Total UK transplants	1017 (100)	994 (100)	958 (100)	736 (100)	838 (100)	884 (100)	864 (100)	879 (100)	916 (100)

3.5.2. **Figure 15** shows the number of transplants over the time periods of interest, by transplant centre and donor type.

Figure 15 Number of deceased donor liver transplants performed in the UK by transplant centre and donor type, 20 March 2017 - 19 March 2026



3.5.3. One hundred and forty of the adult elective liver and liver/kidney transplants were performed in the UK between 27 March 2020 and 9 July 2020. These transplants are **included** in the rest of the section but note that DBD livers were not offered through the National Liver Offering Scheme due to COVID-19, and both DBD and DCD livers were offered to clinically urgent patients. Sixteen NHS group 2 transplants (1 performed at London Bridge and 15 performed at King's College) and three intestinal liver only transplants performed at Cambridge between August 2017 and September 2018 have been excluded from the rest of this section.

3.5.4. **Table 15** and **Table 16** show the demographics of adult elective liver and liver/kidney DBD and DCD transplants performed in the UK during the time periods of interest.

Table 15 Adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

LAG(26)03

	2017/18 N (%) 635	2018/19 N (%) 621	2019/20 N (%) 607	2020/21 N (%) 476	2021/22 N (%) 481	2022/23 N (%) 449	2023/24 N (%) 452	2024/25 N (%) 415	2025/26 N (%) 408
Total									
Offer type									
Named patient		491 (79.1)	441 (72.7)	344 (72.3)	395 (82.1)	378 (84.2)	362 (80.1)	315 (75.9)	325 (79.7)
Fast-track		130 (20.9)	166 (27.3)	132 (27.7)	86 (17.9)	71 (15.8)	90 (19.9)	100 (24.1)	83 (20.3)
Rank on matching run									
Median (IQR)		2 (1 - 4)	2 (1 - 4)	2 (1 - 5)	2 (1 - 4)	2 (1 - 3)	2 (1 - 4)	2 (1 - 4)	2 (1 - 3)
(Range)		(1 - 187)	(1 - 191)	(1 - 204)	(1 - 363)	(1 - 415)	(1 - 317)	(1 - 280)	(1 - 178)
Transplant Benefit Score									
Median (IQR)		1131.98 (881 – 1301)	1096.12 (885 – 1289)	1090.12 (838 – 1281)	1155.1 (923 – 1314)	1170.78 (1014 – 1317)	1136.7 (953 – 1314)	1105.8 (897 – 1241)	1130.4 (939.66 – 1290.43)
(Range)		(-493 – 1617)	(-549 – 1616)	(-1535 - 1563)	(-289 – 1600)	(-215 – 1635)	(-52 – 1601)	(-164 – 1649)	(-16 – 1593)
Transplant Type									
Liver only	615 (96.9)	608 (97.9)	593 (97.7)	469 (98.5)	475 (98.8)	443 (98.7)	445 (98.5)	411 (99.0)	404 (99.0)
Liver & kidney	20 (3.1)	13 (2.1)	14 (2.3)	7 (1.5)	6 (1.2)	6 (1.3)	7 (1.5)	4 (1.0)	4 (1.0)
Type of Liver Transplanted									
Whole liver	596 (93.9)	581 (93.6)	569 (93.7)	443 (93.1)	447 (92.9)	419 (93.3)	422 (93.4)	384 (92.5)	377 (92.4)
Split liver	39 (6.1)	40 (6.4)	37 (6.1)	33 (6.9)	34 (7.1)	28 (6.2)	29 (6.4)	30 (7.2)	31 (7.6)
Reduced liver	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	2 (0.4)	1 (0.2)	1 (0.2)	0 (0)
Recipient Age Group									
17-25 years	27 (4.3)	37 (6.0)	35 (5.8)	34 (7.1)	25 (5.2)	22 (4.9)	21 (4.6)	21 (5.1)	19 (4.7)
26-39 years	95 (15.0)	68 (11.0)	64 (10.5)	41 (8.6)	49 (10.2)	47 (10.5)	58 (12.8)	51 (12.3)	51 (12.5)
40-49 years	98 (15.4)	75 (12.1)	68 (11.2)	78 (16.4)	85 (17.7)	53 (11.8)	55 (12.2)	51 (12.3)	53 (13.0)
50-59 years	208 (32.8)	201 (32.4)	213 (35.1)	170 (35.7)	133 (27.7)	131 (29.2)	126 (27.9)	121 (29.2)	115 (28.2)
60-69 years	193 (30.4)	232 (37.4)	212 (34.9)	144 (30.3)	174 (36.2)	187 (41.6)	182 (40.3)	161 (38.8)	159 (39.0)
70+ years	14 (2.2)	8 (1.3)	15 (2.5)	9 (1.9)	15 (3.1)	9 (2.0)	10 (2.2)	10 (2.4)	11 (2.7)
Recipient Sex									
Male	395 (62.2)	395 (63.6)	369 (60.8)	297 (62.4)	318 (66.1)	275 (61.2)	287 (63.5)	258 (62.2)	240 (58.8)
Female	240 (37.8)	226 (36.4)	238 (39.2)	179 (37.6)	163 (33.9)	174 (38.8)	165 (36.5)	157 (37.8)	168 (41.2)

Type of Patient									
CLD	477 (75.1)	485 (78.1)	471 (77.6)	398 (83.6)	401 (83.4)	362 (80.6)	338 (74.8)	314 (75.7)	302 (74)
HCC	104 (16.4)	72 (11.6)	80 (13.2)	54 (11.3)	39 (8.1)	45 (10.0)	57 (12.6)	44 (10.6)	46 (11.3)
VS	49 (7.7)	59 (9.5)	51 (8.4)	21 (4.4)	28 (5.8)	29 (6.5)	35 (7.7)	36 (8.7)	35 (8.6)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	10 (2.1)	13 (2.9)	21 (4.6)	21 (5.1)	23 (5.6)
HCC downstaging	5 (0.8)	5 (0.8)	5 (0.8)	3 (0.6)	3 (0.6)	0 (0)	1 (0.2)	0 (0)	2 (0.5)
Robert's Disease Group									
HCC	109 (17.2)	78 (12.6)	85 (14.0)	57 (12.0)	45 (9.4)	49 (10.9)	58 (12.8)	49 (11.8)	49 (12)
HCV	23 (3.6)	12 (1.9)	16 (2.6)	9 (1.9)	6 (1.2)	4 (0.9)	7 (1.5)	8 (1.9)	1 (0.2)
ALD	139 (21.9)	169 (27.2)	153 (25.2)	127 (26.7)	149 (31.0)	136 (30.3)	128 (28.3)	114 (27.5)	125 (30.6)
HBV	8 (1.3)	13 (2.1)	5 (0.8)	2 (0.4)	11 (2.3)	7 (1.6)	6 (1.3)	5 (1.2)	8 (2)
PSC	86 (13.5)	72 (11.6)	63 (10.4)	47 (9.9)	56 (11.6)	57 (12.7)	71 (15.7)	54 (13.0)	49 (12)
PBC	37 (5.8)	49 (7.9)	47 (7.7)	43 (9.0)	37 (7.7)	33 (7.3)	29 (6.4)	29 (7.0)	23 (5.6)
AID	44 (6.9)	51 (8.2)	48 (7.9)	38 (8.0)	38 (7.9)	27 (6.0)	33 (7.3)	24 (5.8)	25 (6.1)
NAFLD	67 (10.6)	71 (11.4)	71 (11.7)	54 (11.3)	68 (14.1)	69 (15.4)	56 (12.4)	54 (13.0)	39 (9.6)
Metabolic (excl. NAFLD)	8 (1.3)	13 (2.1)	23 (3.8)	7 (1.5)	9 (1.9)	9 (2.0)	8 (1.8)	9 (2.2)	3 (0.7)
Other	58 (9.1)	40 (6.4)	44 (7.2)	38 (8.0)	35 (7.3)	27 (6.0)	30 (6.6)	33 (8.0)	39 (9.6)
Retransplant	56 (8.8)	53 (8.5)	52 (8.6)	54 (11.3)	27 (5.6)	31 (6.9)	26 (5.8)	36 (8.7)	47 (11.5)
Liver Transplant Number									
First liver transplant	579 (91.2)	567 (91.3)	555 (91.4)	421 (88.4)	454 (94.4)	418 (93.1)	426 (94.2)	379 (91.3)	361 (88.5)
Second	46 (7.2)	51 (8.2)	41 (6.8)	45 (9.5)	18 (3.7)	26 (5.8)	24 (5.3)	34 (8.2)	38 (9.3)
Third	7 (1.1)	3 (0.5)	8 (1.3)	9 (1.9)	8 (1.7)	4 (0.9)	2 (0.4)	2 (0.5)	9 (2.2)
Fourth	2 (0.3)	0 (0)	3 (0.5)	1 (0.2)	1 (0.2)	1 (0.2)	0 (0)	0 (0)	0 (0)
Sixth	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Blood Group Compatibility*									
Identical	628 (98.9)	607 (97.7)	574 (94.6)	451 (94.7)	460 (95.8)	426 (94.9)	436 (96.7)	395 (95.2)	389 (95.6)
Compatible	6 (0.9)	14 (2.3)	33 (5.4)	25 (5.3)	20 (4.2)	23 (5.1)	15 (3.3)	20 (4.8)	18 (4.4)
Incompatible	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Zonal Transplants									
Non zonal	167 (26.3)	487 (78.4)	486 (80.1)	398 (83.6)	389 (80.9)	360 (80.2)	365 (80.8)	342 (82.4)	341 (83.6)
Zonal	468 (73.7)	134 (21.6)	121 (19.9)	78 (16.4)	92 (19.1)	89 (19.8)	87 (19.2)	73 (17.6)	67 (16.4)

Blood group matching* (D=donor, R=recipient)									
DO, RO	297 (46.8)	294 (47.3)	262 (43.2)	182 (38.2)	171 (35.6)	156 (34.7)	212 (47.0)	168 (40.5)	159 (39.1)
DO, RA	1 (0.2)	0 (0)	3 (0.5)	5 (1.1)	8 (1.7)	7 (1.6)	7 (1.6)	6 (1.4)	4 (1.0)
DO, RB	1 (0.2)	1 (0.2)	5 (0.8)	5 (1.1)	5 (1)	6 (1.3)	3 (0.7)	5 (1.2)	3 (0.7)
DO, RAB	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)	1 (0.2)
DA, RO	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
DA, RA	245 (38.6)	235 (37.8)	235 (38.7)	203 (42.6)	213 (44.4)	217 (48.3)	156 (34.6)	167 (40.2)	170 (41.8)
DA, RAB	4 (0.6)	11 (1.8)	20 (3.3)	10 (2.1)	6 (1.3)	9 (2.0)	5 (1.1)	8 (1.9)	9 (2.2)
DB, RB	70 (11.0)	55 (8.9)	59 (9.7)	55 (11.6)	52 (10.8)	43 (9.6)	50 (11.1)	47 (11.3)	44 (10.8)
DB, RAB	0 (0)	2 (0.3)	5 (0.8)	5 (1.1)	1 (0.2)	1 (0.2)	0 (0)	0 (0)	1 (0.2)
DAB, RAB	16 (2.5)	23 (3.7)	18 (3)	11 (2.3)	24 (5.0)	10 (2.2)	18 (4.0)	13 (3.1)	16 (3.9)

*3 transplants performed with unknown donor blood group, one in 2021/22, 2023/24 and 2025/26

Table 16 Adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18 N (%)	2018/19 N (%)	2019/20 N (%)	2020/21 N (%)	2021/22 N (%)	2022/23 N (%)	2023/24 N (%)	2024/25 N (%)	2025/26 N (%)
Total	186	182	170	110	189	243	257	310	368
Transplant Type									
Liver only	186 (100)	182 (100)	169 (99.4)	110 (100)	189 (100)	241 (99.2)	254 (98.8)	307 (99.0)	366 (99.5)
Liver & kidney	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	2 (0.8)	3 (1.2)	3 (1.0)	2 (0.5)
Recipient Age Group									
17-25 years	4 (2.2)	5 (2.7)	5 (2.9)	1 (0.9)	1 (0.5)	5 (2.1)	1 (0.4)	4 (1.3)	8 (2.2)
26-39 years	10 (5.4)	17 (9.3)	16 (9.4)	14 (12.7)	19 (10.1)	30 (12.3)	31 (12.1)	30 (9.7)	58 (15.8)
40-49 years	24 (12.9)	23 (12.6)	25 (14.7)	17 (15.5)	35 (18.5)	39 (16.0)	36 (14.0)	63 (20.3)	66 (17.9)
50-59 years	76 (40.9)	73 (40.1)	55 (32.4)	36 (32.7)	83 (43.9)	82 (33.7)	83 (32.3)	109 (35.2)	110 (29.9)
60-69 years	66 (35.5)	58 (31.9)	68 (40.0)	39 (35.5)	48 (25.4)	82 (33.7)	101 (39.3)	99 (31.9)	118 (32.1)
70+ years	6 (3.2)	6 (3.3)	1 (0.6)	3 (2.7)	3 (1.6)	5 (2.1)	5 (1.9)	5 (1.6)	8 (2.2)
Recipient Sex									
Male	119 (64.0)	130 (71.4)	106 (62.4)	76 (69.1)	132 (69.8)	180 (74.1)	186 (72.4)	223 (71.9)	230 (62.5)
Female	67 (36.0)	52 (28.6)	64 (37.6)	34 (30.9)	57 (30.2)	63 (25.9)	71 (27.6)	87 (28.1)	138 (37.5)
Type of Patient									
CLD	123 (66.1)	87 (47.8)	107 (62.9)	72 (65.5)	104 (55.0)	145 (59.7)	164 (63.8)	205 (66.1)	243 (66)
HCC	52 (28.0)	83 (45.6)	58 (34.1)	33 (30.0)	73 (38.6)	84 (34.6)	75 (29.2)	81 (26.1)	90 (24.5)
VS	9 (4.8)	5 (2.7)	1 (0.6)	2 (1.8)	8 (4.2)	12 (4.9)	13 (5.1)	17 (5.5)	27 (7.3)
HCC downstaging	2 (1.1)	7 (3.8)	4 (2.4)	3 (2.7)	3 (1.6)	2 (0.8)	4 (1.6)	6 (1.9)	7 (1.9)
ACLF	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.5)	0 (0)	1 (0.4)	1 (0.3)	1 (0.3)
Liver Transplant Number									
First liver transplant	183 (98.4)	177 (97.3)	167 (98.2)	103 (93.6)	183 (96.8)	239 (98.4)	249 (96.9)	300 (96.8)	348 (94.6)
Second	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	4 (2.1)	3 (1.2)	7 (2.7)	10 (3.2)	17 (4.6)
Third	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.1)	1 (0.4)	1 (0.4)	0 (0)	3 (0.8)
Blood Group Compatibility*									
Identical	185 (99.5)	175 (96.2)	161 (94.7)	109 (99.1)	182 (96.3)	234 (96.3)	251 (97.7)	302 (97.4)	360 (98.1)
Compatible	1 (0.5)	7 (3.8)	9 (5.3)	1 (0.9)	7 (3.7)	9 (3.7)	6 (2.3)	8 (2.6)	7 (1.9)

Robert's Disease Group									
HCC	55 (29.6)	91 (50.0)	62 (36.5)	36 (32.7)	76 (40.2)	88 (36.2)	80 (31.1)	87 (28.1)	97 (26.4)
HCV	4 (2.2)	3 (1.6)	3 (1.8)	2 (1.8)	6 (3.2)	3 (1.2)	5 (1.9)	1 (0.3)	5 (1.4)
ALD	43 (23.1)	35 (19.2)	43 (25.3)	20 (18.2)	41 (21.7)	57 (23.5)	47 (18.3)	73 (23.5)	74 (20.1)
HBV	3 (1.6)	1 (0.5)	2 (1.2)	1 (0.9)	3 (1.6)	6 (2.5)	5 (1.9)	5 (1.6)	2 (0.5)
PSC	19 (10.2)	12 (6.6)	17 (10.0)	16 (14.5)	15 (7.9)	29 (11.9)	29 (11.3)	37 (11.9)	43 (11.7)
PBC	24 (12.9)	7 (3.8)	18 (10.6)	9 (8.2)	10 (5.3)	14 (5.8)	16 (6.2)	25 (8.1)	27 (7.3)
AID	10 (5.4)	7 (3.8)	5 (2.9)	4 (3.6)	10 (5.3)	14 (5.8)	20 (7.8)	23 (7.4)	26 (7.1)
NAFLD	21 (11.3)	13 (7.1)	8 (4.7)	8 (7.3)	10 (5.3)	17 (7.0)	28 (10.9)	21 (6.8)	32 (8.7)
Metabolic (excluding NAFLD)	4 (2.2)	2 (1.1)	1 (0.6)	3 (2.7)	1 (0.5)	2 (0.8)	3 (1.2)	4 (1.3)	4 (1.1)
Other	0 (0)	6 (3.3)	8 (4.7)	4 (3.6)	11 (5.8)	9 (3.7)	16 (6.2)	24 (7.7)	39 (10.6)
Retransplant	3 (1.6)	5 (2.7)	3 (1.8)	7 (6.4)	6 (3.2)	4 (1.6)	8 (3.1)	10 (3.2)	19 (5.2)
Zonal Transplants									
Non zonal	65 (34.9)	75 (41.2)	65 (38.2)	42 (38.2)	77 (40.7)	86 (35.4)	72 (28.0)	124 (40.0)	132 (35.9)
Zonal	121 (65.1)	107 (58.8)	105 (61.8)	68 (61.8)	112 (59.3)	157 (64.6)	185 (72.0)	186 (60.0)	236 (64.1)
Blood group matching (D=donor, R=recipient)*									
DO, RO	95 (51.1)	79 (43.4)	68 (40)	52 (47.3)	88 (46.6)	115 (47.3)	125 (48.6)	128 (41.3)	164 (44.7)
DO, RA	0 (0)	0 (0)	3 (1.8)	1 (0.9)	4 (2.1)	2 (0.8)	0 (0)	5 (1.6)	3 (0.8)
DO, RB	0 (0)	5 (2.7)	5 (2.9)	0 (0)	2 (1.1)	6 (2.5)	5 (1.9)	1 (0.3)	4 (1.1)
DO, RAB	0 (0)	1 (0.5)	0 (0)	0 (0)	1 (0.5)	0 (0)	0 (0)	0 (0)	0 (0)
DA, RA	70 (37.6)	75 (41.2)	77 (45.3)	48 (43.6)	73 (38.6)	88 (36.2)	94 (36.6)	134 (43.2)	156 (42.5)
DA, RAB	1 (0.5)	1 (0.5)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	2 (0.6)	0 (0)
DB, RB	18 (9.7)	16 (8.8)	13 (7.6)	7 (6.4)	21 (11.1)	27 (11.1)	28 (10.9)	32 (10.3)	33 (9.0)
DB, RAB	0 (0)	0 (0)	1 (0.6)	0 (0)	0 (0)	0 (0)	1 (0.4)	0 (0)	0 (0)
DAB, RAB	2 (1.1)	5 (2.7)	3 (1.8)	2 (1.8)	0 (0)	4 (1.6)	4 (1.6)	8 (2.6)	7 (1.9)

*1 transplant performed with unknown donor blood group in 2025/26

3.5.5. **Table 17(a&b)** and **Table 18(a&b)** show the median waiting time to transplant for the adult elective transplants performed in the UK by transplant centre, blood group and type of patient, for DBD and DCD transplants respectfully. Overall, the median time to transplant was statistically significantly different across the time periods of interest for both DBD and DCD transplants (both with a Kruskal-Wallis p-value<0.0001).

Table 17a Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Overall (N)	635	621	607	476	481	449	452	415	408
Median (IQR)	71 (23, 198)	39 (10, 138)	43 (10, 144)	42.5 (9, 161.5)	33 (9, 105)	40 (9, 156)	58 (14, 192)	59 (14, 198)	48.5 (11, 159)
Range	0 - 1835	1 - 1711	0 - 1620	0 - 1814	0 - 1470	117975	1 - 1420	1 - 1647	0 - 1780
Type of patient									
CLD (N)	477	485	471	398	401	362	338	314	302
Median (IQR)	65 (20, 186)	30 (8, 96)	25 (8, 93)	31.5 (8, 136)	25 (8, 82)	28.5 (8, 123)	40 (12, 147)	40.5 (12, 159)	36 (9, 137)
Range	0 - 1519	1 - 1518	0 - 1450	0 - 1814	0 - 1470	1 - 2223	1 - 915	1 - 1556	1 - 1474
HCC (N)	104	72	80	54	39	45	57	44	46
Median (IQR)	57 (23, 184)	55 (22.5, 145)	79 (33.5, 167.5)	62 (24, 128)	53 (21, 107)	77 (27, 179)	109 (40, 238)	79.5 (31, 163)	48 (13, 137)
Range	2 - 1030	1 - 568	1 - 739	0 - 664	2 - 1400	1 - 769	8 - 1420	3 - 1004	0 - 581
VS (N)	49	59	51	21	28	29	35	36	35
Median (IQR)	187 (79, 543)	296 (100, 836)	365 (174, 613)	367 (261, 585)	385 (200, 612)	570 (264, 880)	369 (129, 833)	294.5 (166, 599)	158 (77, 647)
Range	2 - 1835	2 - 1711	16 - 1620	3 - 1260	17 - 1326	20 - 2100	5 - 1401	10 - 1300	3 - 1780
ACLF (N)	0	0	0	0	10	13	21	21	23
Median (IQR)	-	-	-	-	11.5 (5, 42)	10 (7, 63)	12 (4, 46)	7 (3, 169)	39 (4, 318)
Range	-	-	-	-	2 - 968	2 - 1014	1 - 333	2 - 1647	1 - 1321
HCC downstaging (N)	5	5	5	3	3	0	1	0	2
Median (IQR)	93 (63, 131)	14 (10, 27)	58 (22, 128)	44 (4, 240)	42 (31, 115)	-	71 (-)	-	86 (74, 98)
Range	16 - 384	6 - 65	17 - 204	4 - 240	31 - 115	-	-	-	74 - 98

Table 17b Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026 **LAG(26)03**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Centre									
Newcastle (N)	30	22	26	27	23	14	17	21	11
Median (IQR)	47 (17, 111)	43 (17, 96)	28.5 (14, 85)	43 (9, 190)	45 (13, 110)	8.5 (5, 45)	22 (12, 164)	30 (8, 78)	31 (2, 159)
Range	1 - 377	2 - 318	1 - 517	2 - 607	2 - 760	4 - 998	4 - 1233	3 - 485	2 - 664
Leeds (N)	108	66	79	70	60	74	71	79	61
Median (IQR)	64.5 (26, 228.5)	41.5 (9, 145)	33 (9, 136)	52.5 (14, 159)	27.5 (9, 113)	22.5 (7, 133)	41 (12, 137)	74 (15, 180)	69 (28, 128)
Range	1 - 1402	1 - 1341	1 - 1405	1 - 1260	1 - 1187	1 - 1058	1 - 873	2 - 1454	2 - 1780
Cambridge (N)	71	65	60	35	50	40	52	45	38
Median (IQR)	74 (21, 200)	36 (10, 88)	17 (8.5, 67)	23 (9, 76)	37 (9, 90)	15 (7, 62.5)	20 (7, 73.5)	27 (6, 80)	24.5 (8, 98)
Range	0 - 1343	1 - 760	1 - 656	0 - 679	0 - 633	1 - 407	1 - 753	2 - 1285	2 - 1031
Royal Free (N)	84	83	91	57	65	68	68	73	65
Median (IQR)	99.5 (29.5, 236.5)	33 (7, 133)	37 (11, 96)	37 (8, 79)	28 (8, 154)	50 (11, 141)	54 (14.5, 234)	45 (11, 197)	30 (8, 98)
Range	0 - 945	1 - 1261	1 - 971	0 - 669	2 - 592	2 - 1453	2 - 1004	1 - 985	1 - 456
Kings College (N)	128	143	145	115	117	98	103	83	110
Median (IQR)	125 (45, 374)	54 (11, 252)	54 (11, 164)	32 (8, 140)	33 (9, 98)	85.5 (11, 288)	93 (26, 265)	83 (21, 319)	56.5 (11, 213)
Range	1 - 1813	1 - 1711	1 - 1620	0 - 1687	1 - 968	2 - 2100	1 - 1286	1 - 1647	0 - 1503
Birmingham (N)	133	154	154	114	127	115	110	79	88
Median (IQR)	48 (15, 137)	42.5 (11, 105)	58.5 (9, 204)	71.5 (8, 262)	34 (9, 146)	65 (16, 286)	89 (22, 235)	95 (16, 333)	63.5 (10, 248.5)
Range	0 - 1519	1 - 1657	0 - 976	1 - 1814	1 - 1470	1 - 2223	1 - 1420	1 - 1556	1 - 1474
Edinburgh (N)	81	88	52	58	39	40	31	35	35
Median (IQR)	42 (12, 109)	24.5 (6, 115.5)	46.5 (19, 140)	45.5 (9, 239)	17 (7, 39)	22.5 (8, 58)	76 (30, 191)	31 (16, 136)	39 (9, 131)
Range	0 - 1835	1 - 1124	2 - 640	1 - 749	1 - 452	2 - 218	3 - 1401	2 - 1274	1 - 988
Recipient blood group									
O (N)	298	294	262	182	171	156	212	168	159
Median (IQR)	113.5 (32, 280)	60 (14, 218)	56.5 (12, 188)	52.5 (11, 216)	37 (10, 132)	58 (11.5, 204)	60.5 (13, 228.5)	58 (14, 198.5)	50 (14, 190)
Range	0 - 1835	1 - 1711	1 - 1620	0 - 1814	0 - 1470	1 - 1453	1 - 1420	1 - 1454	1 - 1780
A (N)	246	235	238	208	221	224	163	173	174
Median (IQR)	40 (16, 93)	23 (7, 77)	33 (9, 100)	27 (7, 138)	27 (8, 100)	30 (9, 148)	61 (14, 181)	56 (12, 197)	36 (8, 148)
Range	0 - 1109	1 - 1056	0 - 758	0 - 786	1 - 918	1 - 2223	2 - 1004	1 - 985	0 - 1321
B (N)	71	56	64	60	57	49	53	52	47
Median (IQR)	168 (49, 384)	57 (15, 132)	66 (18.5, 167.5)	66 (21.5, 279.5)	33 (9, 103)	50 (23, 173)	64 (31, 162)	79 (30.5, 279)	97 (32, 293)
Range	0 - 1813	2 - 1518	2 - 865	2 - 1335	2 - 592	2 - 2100	1 - 1233	2 - 1647	1 - 1324
AB (N)	20	36	43	26	32	20	24	22	28
Median (IQR)	25.5 (7.5, 66)	39.5 (13, 93)	19 (4, 43)	27 (13, 78)	24 (8, 57)	11 (5.5, 25.5)	32.5 (15, 73.5)	41 (5, 79)	21.5 (5.5, 70.5)
Range	0 - 148	1 - 466	1 - 201	5 - 340	2 - 388	1 - 63	2 - 302	2 - 1556	1 - 186

Table 18a Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Overall (N)	186	182	170	110	189	243	257	310	368
Median (IQR)	41.5 (14, 142)	53 (20, 128)	52 (19, 142)	90.5 (29, 205)	98 (38, 163)	132 (50, 306)	137 (43, 294)	133.5 (49, 340)	141 (41, 313)
Range	0 - 875	0 - 607	2 - 693	2 - 1278	1 - 923	1 - 1242	1 - 1395	0 - 2358	0 - 2918
Type of patient									
CLD (N)	123	87	107	72	104	145	164	205	243
Median (IQR)	41 (13, 143)	55 (19, 125)	50 (15, 147)	104.5 (35.5, 205.5)	102 (29.5, 178)	139 (49, 328)	143.5 (50, 309)	177 (60, 360)	156 (49, 319)
Range	0 - 875	0 - 561	2 - 693	2 - 1101	1 - 923	1 - 1242	1 - 1395	0 - 2358	2 - 2864
HCC (N)	52	83	58	33	73	84	75	81	90
Median (IQR)	39.5 (16.5, 110)	49 (20, 148)	66.5 (35, 135)	73 (29, 144)	95 (45, 157)	122 (47, 269.5)	110 (29, 244)	96 (42, 201)	102.5 (28, 255)
Range	1 - 691	2 - 607	4 - 322	5 - 1278	2 - 822	2 - 868	2 - 787	3 - 1187	0 - 1369
VS (N)	9	5	1	2	8	12	13	17	27
Median (IQR)	222 (32, 347)	98 (72, 300)	559 (559, 559)	218 (215, 221)	154 (103.5, 254.5)	191.5 (68, 238)	163 (79, 381)	453 (83, 691)	250 (94, 688)
Range	7 - 870	5 - 306	559 - 559	215 - 221	70 - 396	51 - 636	25 - 905	4 - 1067	15 - 2918
ACLF (N)	0	0	0	0	1	0	1	1	1
Median (IQR)	-	-	-	-	2 (-)	-	1 (-)	5 (-)	5 (-)
Range	-	-	-	-	2	-	1	5	5
HCC downstaging (N)	2	7	4	3	3	2	4	6	7
Median (IQR)	53 (51, 55)	47 (17, 84)	21 (12, 35.5)	72 (27, 216)	52 (24, 143)	102.5 (94, 111)	70.5 (12.5, 200)	59.5 (24, 103)	30 (10, 62)
Range	51 - 55	11 - 323	12 - 41	27 - 216	24 - 143	94 - 111	8 - 276	22 - 135	2 - 232

Table 18b Median (IQR; range) time to transplant (days) for adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Centre									
Newcastle (N)	5	3	4	2	13	14	25	19	15
Median (IQR)	106 (85, 304)	304 (22, 452)	144.5 (119,371)	110 (4, 216)	152 (117, 394)	173 (47, 247)	42 (24, 137)	42 (6, 65)	36 (14, 157)
Range	5 - 347	22 - 452	103 - 588	4 - 216	5 - 817	26 - 770	2 - 1169	3 - 187	5 - 793
Leeds (N)	26	21	21	15	16	26	36	17	35
Median (IQR)	77.5 (13, 297)	36 (12, 99)	36 (12, 73)	56 (26, 133)	115.5 (52, 147)	118.5 (46, 362)	234 (72, 501.5)	209 (116, 427)	116 (26, 333)
Range	0 - 875	2 - 517	2 - 565	5 - 511	4 - 923	13 - 868	1 - 1128	24 - 893	2 - 1369
Cambridge (N)	32	40	33	35	48	53	51	59	62
Median (IQR)	60 (28.5, 151.5)	57.5 (21.5, 128)	35 (14, 78)	89 (46, 211)	63 (21.5, 142.5)	111 (29, 210)	76 (43, 213)	108 (41, 287)	85.5 (31, 176)
Range	0 - 870	2 - 355	2 - 479	5 - 625	1 - 822	2 - 832	6 - 779	0 - 1111	0 - 1225
Royal Free (N)	13	28	37	11	23	18	30	45	44
Median (IQR)	62 (24, 234)	56.5 (29.5, 144)	55 (23, 135)	57 (23, 205)	94 (27, 148)	139.5 (67, 388)	53.5 (20, 136)	96 (37, 155)	66.5 (19.5, 153)
Range	3 - 369	2 - 323	4 - 693	11 - 227	8 - 327	5 - 911	3 - 740	3 - 2358	2 - 1007
Kings College (N)	46	38	37	31	46	51	49	60	111
Median (IQR)	67 (27, 205)	72.5 (34, 180)	84 (38, 198)	123 (54, 189)	133.5 (52, 162)	198 (92, 341)	190 (94, 375)	215 (114.5,354)	227 (87, 490)
Range	4 - 691	4 - 607	3 - 559	8 - 1101	1 - 342	1 - 716	1 - 1093	5 - 1067	4 - 2918
Birmingham (N)	52	39	33	11	25	54	34	85	69
Median (IQR)	22.5 (13, 42.5)	34 (14, 80)	50 (30, 125)	115 (7, 221)	94 (60, 218)	111 (42, 258)	145 (69, 381)	238 (46, 409)	174 (102, 480)
Range	0 - 511	0 - 487	2 - 267	2 - 259	12 - 418	2 - 1039	1 - 987	3 - 1187	1 - 2628
Edinburgh (N)	12	13	5	5	18	27	32	25	32
Median (IQR)	41.5 (10, 94.5)	71 (38, 333)	51 (44, 151)	42 (30, 777)	52.5 (16, 151)	137 (38, 471)	228 (44, 304.5)	116 (58, 350)	107.5 (40, 283.5)
Range	0 - 783	6 - 383	40 - 224	27 - 1278	2 - 738	2 - 1242	4 - 1395	29 - 1435	14 - 778
Recipient blood group									
O (N)	95	79	68	52	88	115	125	128	164
Median (IQR)	62 (16, 245)	69 (28, 175)	69 (19, 163.5)	115.5 (28, 222)	117 (45.5, 182.5)	158 (75, 355)	170 (56, 334)	189 (61.5, 389)	162.5 (72, 419.5)
Range	0 - 875	0 - 561	2 - 693	7 - 1278	1 - 822	2 - 1242	1 - 1169	3 - 1435	2 - 2918
A (N)	70	75	80	49	77	90	94	139	159
Median (IQR)	29 (10, 65)	37 (17, 78)	50 (19, 100.5)	78 (26, 189)	93 (28, 143)	104.5 (42, 236)	114 (39, 272)	116 (41, 325)	103 (30, 251)
Range	0 - 351	2 - 457	2 - 588	2 - 530	2 - 476	2 - 911	1 - 1395	0 - 2358	0 - 2864
B (N)	18	21	18	7	23	33	33	33	37
Median (IQR)	55 (19, 262)	103 (30, 171)	87 (43, 183)	92 (57, 119)	86 (40, 271)	147 (64, 243)	67 (38, 277)	145 (83, 266)	139 (31, 273)
Range	4 - 783	4 - 607	2 - 479	29 - 446	1 - 923	4 - 868	6 - 787	17 - 1007	5 - 1164
AB (N)	3	7	4	2	1	5	5	10	8
Median (IQR)	27 (9, 111)	23 (9, 94)	7.5 (6.5, 22)	60.5 (48, 73)	77 (77, 77)	2 (2, 41)	14 (9, 22)	55.5 (11, 74)	27.5 (17.5, 138.5)
Range	9 - 111	6 - 111	6 - 36	48 - 73	77 - 77	1 - 60	1 - 79	3 - 132	4 - 333

3.5.6. **Figure 16** shows the overall cold ischaemia time for the time periods of interest for DBD transplants while **Figure 17** shows the cold ischaemia time for each centre. **Figures 18** and **Figure 19** show the equivalent information for DCD donor transplants.

3.5.7. There were statistically significant differences in the cold ischaemia time for adult elective DBD and DCD transplants over the time periods of interest ($p=0.001$ for DBD and $p<0.001$ for DCD). However, it should be noted that these results will change as NHSBT has not received all the first week transplant record forms which collect the cold ischaemia time. It should also be noted that this analysis does not adjust for whether machine perfusion was used.





Figure 18 Median cold ischaemia time in all adult elective DCD donor liver transplants, by time period, 20 March 2017 to 19 March 2026





Figure 19 Median cold ischaemia time in all adult elective DCD donor liver transplants, by transplant centre, 20 March 2017 - 19 March 2026



3.6. NINETY-DAY POST-TRANSPLANT SURVIVAL

3.6.1. **Figure 20** shows the unadjusted ninety-day patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first ninety-three months of NLOS. **Table 20a** and **Table 20b** shows the survival estimates and confidence intervals by blood group and type of patient for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.

3.6.2. For DBD transplants, there was no overall statistically significant difference between the time periods of interest in ninety-day patient survival (log-rank p-value=0.34). There was a statistically significant difference in ninety-day survival for CLD patients (log-rank p-value=0.03) and HCC patients (log-rank p-value=0.03). There were no statistically significant differences between the time periods for the individual centres (log-rank p-value $\geq$ 0.18) and blood groups (log-rank p-value $\geq$ 0.28), apart from blood group B patients which had significance (p=0.03).

3.6.3. For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in ninety-day patient survival (log-rank p-value=0.08). There were no statistically significant differences between the time periods for CLD and HCC (log rank p-value $\geq$ 0.08) and blood groups (log rank p-value $\geq$ 0.33). There were no statistically significant differences between the time periods for the individual centres (log rank p-value $\geq$ 0.08).

Figure 20 Unadjusted ninety day patient survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 December 2025




Table 19 Median hospital stay post-transplant for adult elective liver and liver/kidney transplants performed in the UK using livers from deceased donors, 20 March 2017 to 19 December 2025, as at 10 April 2026

LAG(26)03

	2017/2018	2018/2019	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026 *
DBD									
N	579	567	555	420	454	418	426	379	257
No. (%) with discharge date reported	542 (94)	524 (92)	530 (95)	401 (95)	433 (95)	389 (93)	398 (93)	362 (96)	236 (92)
Median (range) time from transplant to hospital discharge	14 (10 - 20)	13 (10 - 18)	13 (10 - 19)	14 (11 - 21)	15 (11 - 23)	14 (10 - 21)	14 (11 - 23)	15 (11 - 24)	13 (11 - 20)
No. (%) with no discharge date but a death date reported	23 (4)	24 (4.2)	13 (2.3)	12 (2.9)	11 (2.4)	16 (3.8)	14 (3.3)	6 (1.6)	10 (3.9)
Median (range) time from tx to death date	32 (14 - 62)	52 (7 - 194)	41 (2 - 181)	18 (8.5-48.5)	30 (2 - 85)	32.5 (14.5-141.5)	46 (9 - 58)	20.5 (4 - 26)	8.5 (2 - 60)
No. (%) with no discharge or death date reported	14 (2.4)	19 (3.4)	12 (2.2)	7 (1.7)	10 (2.2)	13 (3.1)	14 (3.3)	11 (2.9)	11 (4.3)
DCD									
N	183	177	166	103	183	239	249	300	244
No. (%) with discharge date reported	176 (96)	160 (90)	151 (91)	98 (95)	169 (92)	223 (93)	233 (94)	278 (93)	236 (97)
Median (range) time from transplant to hospital discharge	12.5 (9 - 17)	14 (10 - 19)	13 (9 - 20)	14 (10 - 19)	14 (10 - 20)	13 (10 - 21)	15 (11 - 22)	13 (10 - 19)	14 (10 - 21)
No. (%) with no discharge date but a death date reported	4 (2.2)	10 (5.6)	10 (6)	3 (2.9)	6 (3.3)	6 (2.5)	9 (3.6)	10 (3.3)	4 (1.6)
Median (range) time from tx to death date	44.5 (5 - 1278.5)	23.5 (4 - 190)	27 (1 - 45)	119 (52 - 1382)	105.5 (38 - 183)	35 (19 - 77)	25 (8 - 139)	20.5 (1 - 43)	36.5 (1.5 - 107)
No. (%) with no discharge or death date reported	3 (1.6)	7 (4)	5 (3)	2 (1.9)	8 (4.4)	10 (4.2)	7 (2.8)	12 (4)	4 (1.6)

*includes transplants up to 19 December 2025

Table 20a 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 December 2025										
	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*	Log-rank p-value
Overall (No at risk)	579	567	555	420	454	418	426	379	257	0.3370
% (95% CI)	96.2 (94.3,97.5)	96.5 (94.6,97.7)	98.2 (96.7,99.0)	97.1 (95.0,98.4)	97.8 (95.9,98.8)	96.9 (94.7,98.2)	97.2 (95.1,98.4)	98.4 (96.5,99.3)	96.1 (92.9,97.9)	
Type of patient										
CLD (No at risk)	425	436	423	346	375	333	313	279	192	0.0258
% (95% CI)	95.5 (93.1,97.1)	95.9 (93.5,97.4)	98.1 (96.3,99)	98.3 (96.2,99.2)	98.1 (96.1,99.1)	97.9 (95.6,99)	98.1 (95.8,99.1)	98.6 (96.2,99.5)	99 (95.9,99.7)	
HCC (No at risk)	104	71	80	53	39	45	57	44	25	0.0312
% (95% CI)	98.1 (92.5,99.5)	97.2 (89.2,99.3)	98.8 (91.5,99.8)	90.6 (78.8,96)	97.4 (83.2,99.6)	88.9 (75.3,95.2)	96.5 (86.7,99.1)	100 (-)	92 (71.6,97.9)	
VS (No at risk)	45	55	47	18	27	27	34	35	25	0.4184
% (95% CI)	97.8 (85.3,99.7)	100 (-)	97.9 (85.8,99.7)	94.4 (66.6,99.2)	96.3 (76.5,99.5)	100 (-)	97.1 (80.9,99.6)	100 (-)	91.8 (71.1,97.9)	
HCC downstaging (No at risk)	5	5	5	3	3	0	1	0	1	-
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	-	100 (-)	-	100 (-)	
ACLF (No at risk)	0	0	0	0	10	13	21	21	14	0.4141
% (95% CI)	-	-	-	-	90 (47.3,98.5)	92.3 (56.6,98.9)	85.7 (62.0,95.2)	90.5 (67.0,97.5)	71.4 (40.6,88.2)	
Recipient blood group										
O (No at risk)	272	266	241	162	162	149	195	152	105	0.2834
% (95% CI)	95.2 (91.9,97.2)	97.4 (94.6,98.7)	98.8 (96.2,99.6)	97.5 (93.6,99.1)	97.5 (93.6,99.1)	97.3 (93.0,99.0)	97.9 (94.6,99.2)	98.7 (94.8,99.7)	95.2 (88.9,98.0)	
A (No at risk)	224	214	215	182	205	205	160	158	110	0.7649
% (95% CI)	96.4 (93.0,98.2)	96.3 (92.7,98.1)	97.7 (94.5,99.0)	96.2 (92.1,98.1)	98 (94.9,99.3)	98 (94.9,99.3)	97.5 (93.5,99.1)	98.7 (95.0,99.7)	96.4 (90.6,98.6)	
B (No at risk)	66	53	59	52	55	45	51	49	26	0.0344
% (95% CI)	100 (-)	92.5 (81.1,97.1)	98.3 (88.6,99.8)	98.1 (87.1,99.7)	100 (-)	88.9 (75.3,95.2)	94.1 (82.9,98.1)	98.0 (86.4,99.7)	96.2 (75.7,99.4)	

AB (No at risk)	17	34	40	24	32	19	20	20	16	0.8677
% (95% CI)	94.1 (65.0,99.1)	97.1 (80.9,99.6)	97.5 (83.5,99.6)	100 (-)	93.8 (77.3,98.4)	100 (-)	95.0 (69.5,99.3)	95.0 (69.5,99.3)	100 (-)	
Centre										
Newcastle (No at risk)	26	22	24	24	23	13	17	20	8	0.5545
% (95% CI)	92.3 (72.6,98.0)	95.5 (71.9,99.3)	95.8 (73.9,99.4)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	101	59	73	63	60	68	65	73	40	0.4455
% (95% CI)	93.1 (86,96.6)	91.5 (80.8,96.4)	98.6 (90.7,99.8)	95.2 (86.0,98.4)	95 (85.3,98.4)	97.1 (88.7,99.3)	93.8 (84.4,97.6)	98.6 (90.7,99.8)	92.5 (78.5,97.5)	
Cambridge (No at risk)	67	61	58	28	50	39	52	44	21	0.4069
% (95% CI)	97 (88.6,99.2)	100 (-)	94.8 (84.8,98.3)	100 (-)	100 (-)	100 (-)	96.2 (85.5,99.0)	95.5 (83.0,98.8)	95.2 (70.7,99.3)	
Royal Free (No at risk)	82	80	88	50	61	64	65	70	40	0.3418
% (95% CI)	96.3 (89.1,98.8)	93.8 (85.6,97.3)	100 (-)	98.0 (86.6,99.7)	96.7 (87.5,99.2)	96.9 (88.1,99.2)	96.9 (88.3,99.2)	100 (-)	95.0 (81.5,98.7)	
Kings College (No at risk)	111	128	132	104	110	88	95	70	69	0.8417
% (95% CI)	98.2 (92.9,99.5)	99.2 (94.6,99.9)	98.5 (94.1,99.6)	99.0 (93.4,99.9)	98.2 (92.9,99.5)	100 (-)	98.9 (92.8,99.9)	97.1 (88.7,99.3)	97.1 (88.9,99.3)	
Birmingham (No at risk)	117	133	135	96	113	108	102	70	57	0.3967
% (95% CI)	95.7 (90.0,98.2)	96.2 (91.2,98.4)	99.3 (94.9,99.9)	95.8 (89.3,98.4)	97.3 (92,99.1)	96.3 (90.4,98.6)	99.0 (93.2,99.9)	100 (-)	98.2 (88.2,99.8)	
Edinburgh (No at risk)	75	84	45	55	37	38	30	32	22	0.1764
% (95% CI)	98.7 (90.9,99.8)	96.4 (89.3,98.8)	95.6 (83.4,98.9)	94.5 (84.0,98.2)	100 (-)	86.8 (71.2,94.3)	93.3 (75.9,98.3)	96.9 (79.8,99.6)	95.5 (71.9,99.3)	
*20 March 2025 – 19 December 2025										


Table 20b 90-day patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 December 2025										
	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26*	Log-rank p-value
Overall (No at risk)	183	177	166	103	183	239	249	300	244	0.0818
% (95% CI)	98.4	94.9	94.6	98	98.4	97.9	97.6	96.0	98.8	
	(95.0,99.5)	(90.5,97.3)	(89.8,97.1)	(92.4,99.5)	(95.0,99.5)	(95.0,99.1)	(94.7,98.9)	(93.0,97.7)	(96.2,99.6)	
Type of patient										
CLD (No at risk)	120	83	103	65	98	141	157	195	161	0.1782
% (95% CI)	98.3	95.2	97.1	98.5	99	98.6	98.1	95.9	100 (-)	
	(93.5,99.6)	(87.7,98.2)	(91.2,99.1)	(89.6,99.8)	(93.0,99.9)	(94.4,99.6)	(94.2,99.4)	(91.9,97.9)		
HCC (No at risk)	52	83	58	33	73	84	75	81	59	0.0763
% (95% CI)	98.1	95.2	89.7	97	100 (-)	97.6	97.3	97.5	98.3	
	(87.1,99.7)	(87.7,98.2)	(78.4,95.2)	(80.4,99.6)		(90.8,99.4)	(89.8,99.3)	(90.5,99.4)	(88.6,99.8)	
VS (No at risk)	9	4	1	2	8	12	12	17	18	0.9388
% (95% CI)					87.5	91.7		94.1	94.1	
	100 (-)	100 (-)	100 (-)	100 (-)	(38.7,98.1)	(53.9,98.8)	100 (-)	(65.0,99.1)	(65.0,99.1)	
HCC downstaging (No at risk)	2	7	4	3	3	2	4	6	5	0.9388
% (95% CI)		85.7					75	83.3	80.0	
	100 (-)	(33.4,97.9)	100 (-)	100 (-)	100 (-)	100 (-)	(12.8,96.1)	(27.3,97.5)	(20.4,96.9)	
ACLF (No at risk)	0	0	0	0	1	0	1	1	1	0.3916
% (95% CI)	-	-	-	-	0 (-)	-	100 (-)	100 (-)	100 (-)	
Recipient blood group										
O (No at risk)	95	78	67	48	86	111	119	124	113	0.3277
% (95% CI)	97.9	93.6	94	95.7	98.8	98.2	96.6	96.8	99.1	
	(91.8,99.5)	(85.3,97.3)	(84.9,97.7)	(84.0,98.9)	(92.0,99.8)	(93.0,99.5)	(91.3,98.7)	(91.6,98.8)	(93.8,99.9)	
A (No at risk)	67	72	78	46	74	90	92	133	105	0.6483
% (95% CI)	98.5	98.6	94.9		97.3	97.8	98.9	96.2	98.1	
	(89.9,99.8)	(90.5,99.8)	(86.9,98.0)	100 (-)	(89.6,99.3)	(91.4,99.4)	(92.5,99.8)	(91.1,98.4)	(92.6,99.5)	
B (No at risk)	18	20	18	7	22	33	33	33	21	0.6225

% (95% CI)	100 (-)	90 (65.6,97.4)	94.4 (66.6,99.2)	100 (-)	100 (-)	97.0 (80.4,99.6)	97.0 (80.4,99.6)	97.0 (80.4,99.6)	100 (-)	
AB (No at risk)	3	7	3	2	1	5	5	10	5	0.7869
% (95% CI)	100 (-)	85.7 (33.4,97.9)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	80.0 (40.9,94.6)	100 (-)	
Centre										
Newcastle (No at risk)	4	3	4	2	13	14	25	18	9	0.6951
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	92.9 (59.1,99.0)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	26	20	21	15	16	26	35	17	23	0.5543
% (95% CI)	96.2 (75.7,99.4)	95 (69.5,99.3)	90.5 (67,97.5)	100 (-)	100 (-)	100 (-)	88.6 (72.4,95.5)	94.1 (65.0,99.1)	91.3 (69.5,97.8)	
Cambridge (No risk)	30	37	31	29	43	52	47	57	36	0.6348
% (95% CI)	96.7 (78.6,99.5)	97.3 (82.3,99.6)	93.5 (76.6,98.3)	100 (-)	95.3 (82.7,98.8)	98.1 (87.1,99.7)	100 (-)	96.5 (86.7,99.1)	100 (-)	
Royal Free (No risk)	13	28	36	11	22	18	30	44	31	0.2893
% (95% CI)	100 (-)	92.9 (74.3,98.2)	94.4 (79.6,98.6)	81.8 (44.7,95.1)	100 (-)	88.9 (62.4,97.1)	96.7 (78.6,99.5)	95.5 (83.0,98.8)	100 (-)	
Kings College (No at risk)	46	37	36	30	46	48	46	59	75	0.4966
% (95% CI)	100 (-)	94.6 (80.1,98.6)	97.2 (81.9,99.6)	100 (-)	100 (-)	97.9 (86.1,99.7)	100 (-)	98.3 (88.6,99.8)	98.7 (90.9,99.8)	
Birmingham (No at risk)	52	39	33	11	25	54	34	82	47	0.3150
% (95% CI)	98.1 (87.1,99.7)	92.3 (78.0,97.5)	97 (80.4,99.6)	100 (-)	100 (-)	100 (-)	97.1 (80.9,99.6)	95.1 (87.5,98.1)	100 (-)	
Edinburgh (No at risk)	12	13	5	5	18	27	32	23	23	0.0819
% (95% CI)	100 (-)	100 (-)	80 (20.4,96.9)	100 (-)	94.4 (66.6,99.2)	100 (-)	100 (-)	91.3 (69.5,97.8)	100 (-)	
*20 March 2025 – 19 December 2025										

3.6.4. **Figure 21** shows the unadjusted ninety-day transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first ninety-three months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 90 days.

3.6.5. There were no statistically significant differences in the unadjusted ninety-day transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.73 and 0.52).

Figure 21 Unadjusted ninety day transplant survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 December 2025



3.8 ONE-YEAR POST-TRANSPLANT SURVIVAL

- 3.8.1 **Figure 22** shows the unadjusted one-year patient survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first eighty-four months of NLOS. **Table 21** and **Table 22** shows the survival estimates and confidence intervals by blood group and type of patient, for DBD and DCD transplants respectively. Patient survival was defined as the time from first transplant to death or last known survival reported to NHSBT irrespective of whether the patient received a retransplant after their first transplant.
- 3.8.2 For DBD transplants, there was no overall statistically significant difference between the time periods of interest in one-year patient survival (log-rank p-value=0.45). There was no statistically significant difference between the time periods for CLD and HCC (log rank p-value $\geq$ 0.11) or for the individual centres (log-rank p-value $\geq$ 0.09). There was no statistically significant difference between periods for recipient blood groups (log rank p-value $\geq$ 0.52) except for blood group B (log rank p-value=0.0340).
- 3.8.3 For DCD transplants, there was no overall statistically significant difference at a 5% significance level overall between the time periods in one-year patient survival (log-rank p-value=0.63). There were no statistically significant differences between the two time periods for CLD and HCC (log rank p-value $\geq$ 0.25), blood groups (log rank p-value $\geq$ 0.43) and for the individual centres (log rank p-value $\geq$ 0.30).

Figure 22 Unadjusted one year patient survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 March 2025




Table 21a 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2025									
	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	Log-rank p-value
Overall	579	567	555	420	454	418	426	379	0.4501
(No at risk)									
% (95% CI)	94.6 (92.5,96.2)	94.5 (92.3,96.1)	96.0 (94.0,97.4)	96.4 (94.1,97.8)	94.9 (92.4,96.6)	93.7 (90.9,95.7)	95.3 (92.8,96.9)	96.4 (93.2,98.1)	
Type of patient									
CLD (No at risk)	425	436	423	346	375	333	313	279	0.1131
% (95% CI)	93.9 (91.1,95.8)	94.5 (91.9,96.3)	96.7 (94.5,98.0)	97.4 (95.0,98.6)	95.4 (92.8,97.1)	94.6 (91.5,96.5)	96.2 (93.3,97.8)	97.7 (94.9,98.9)	
HCC (No at risk)	104	71	80	53	39	45	57	44	0.7921
% (95% CI)	96.1 (89.9,98.5)	93.0 (83.9,97.0)	93.8 (85.6,97.3)	90.6 (78.8,96.0)	92.3 (78.0,97.5)	88.9 (75.3,95.2)	92.8 (81.9,97.2)	90.1 (62.6,97.7)	
VS (No at risk)	45	55	47	18	27	27	34	35	0.9858
% (95% CI)	97.8 (85.3,99.7)	96.3 (86.1,99.1)	93.6 (81.5,97.9)	94.4 (66.6,99.2)	96.3 (76.5,99.5)	96.3 (76.5,99.5)	97.1 (80.9,99.6)	96.6 (77.9,99.5)	
HCC downstaging (No at risk)	5	5	5	3	3	0	1	0	-
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	-	100 (-)	-	
Recipient blood group									
O (No at risk)	272	266	241	162	162	149	195	152	0.5155
% (95% CI)	93.7 (90.1,96.1)	94 (90.3,96.3)	96.7 (93.4,98.3)	96.9 (92.7,98.7)	95 (90.3,97.5)	93.9 (88.6,96.8)	95.9 (91.9,97.9)	97.0 (92.3,98.9)	
A (No at risk)	224	214	215	182	205	205	160	158	0.9866
% (95% CI)	95.1 (91.3,97.3)	95.8 (92.1,97.8)	94.9 (90.9,97.1)	95 (90.7,97.4)	95.1 (91.1,97.3)	95.1 (91.0,97.3)	96.9 (92.6,98.7)	95.5 (88.7,98.2)	

B (No at risk)	66	53	59	52	55	45	51	49	0.0340
% (95% CI)	97.0 (88.4,99.2)	92.5 (81.1,97.1)	96.6 (87.1,99.1)	98.1 (87.1,99.7)	98.1 (87.4,99.7)	86.6 (72.6,93.8)	88.2 (75.7,94.5)	98.0 (86.4,99.7)	
AB (No at risk)	17	34	40	24	32	19	20	20	0.6413
% (95% CI)	94.1 (65.0,99.1)	94.0 (78.2,98.5)	97.5 (83.5,99.6)	100 (-)	87.5 (70.0,95.1)	94.7 (68.1,99.2)	95.0 (69.5,99.3)	95.0 (69.5,99.3)	
Centre									
Newcastle (No at risk)	26	22	24	24	23	13	17	20	0.6061
% (95% CI)	92.3 (72.6,98.0)	95.5 (71.9,99.3)	91.7 (70.6,97.8)	100 (-)	95.7 (72.9,99.4)	100 (-)	100 (-)	100 (-)	
Leeds (No at risk)	101	59	73	63	60	68	65	73	0.7791
% (95% CI)	91.1 (83.6,95.3)	89.8 (78.8,95.3)	95.9 (87.8,98.7)	95.2 (86.0,98.4)	91.6 (81.0,96.4)	92.6 (83.1,96.8)	92.2 (82.3,96.7)	94.7 (83.7,98.3)	
Cambridge (No at risk)	67	61	58	28	50	39	52	44	0.0888
% (95% CI)	95.5 (86.8,98.5)	100 (-)	93.1 (82.7,97.4)	100 (-)	98 (86.6,99.7)	100 (-)	90.3 (78.3,95.9)	95.5 (83.0,98.8)	
Royal Free (No at risk)	82	80	88	50	61	64	65	70	0.4324
% (95% CI)	95.1 (87.5,98.1)	91.3 (82.5,95.7)	96.6 (89.7,98.9)	98.0 (86.6,99.7)	96.7 (87.5,99.2)	92.2 (82.2,96.7)	95.3 (86.1,98.5)	98.2 (87.8,99.7)	
Kings College (No at risk)	111	128	132	104	110	88	95	70	0.7074
% (95% CI)	98.2 (92.9,99.5)	96.8 (91.8,98.8)	98.5 (94.1,99.6)	96.0 (89.8,98.5)	96.3 (90.5,98.6)	96.5 (89.5,98.8)	97.9 (91.8,99.5)	93.8 (84.3,97.6)	
Birmingham (No at risk)	117	133	135	96	113	108	102	70	0.3162
% (95% CI)	93.2 (86.8,96.5)	94.7 (89.2,97.4)	95.5 (90.3,98.0)	95.8 (89.3,98.4)	92 (85.3,95.8)	92.6 (85.7,96.2)	97.1 (91.2,99.0)		
Edinburgh (No at risk)	75	84	45	55	37	38	30	32	0.5360
% (95% CI)	96 (88.1,98.7)	92.8 (84.7,96.7)	95.6 (83.4,98.9)	94.5 (84.0,98.2)	97.3 (82.3,99.6)	86.8 (71.2,94.3)	93.3 (75.9,98.3)	96.9 (79.8,99.6)	


Table 21b 1-year patient survival (95% confidence interval) for first adult elective liver and liver/kidney transplants performed in the UK using livers from DCD donors, 20 March 2017 to 19 March 2025									
	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	Log-rank p-value
Overall (No at risk)	183	177	166	103	183	239	249	300	0.6335
% (95% CI)	95.6 (91.4,97.8)	92.6 (87.6,95.7)	92.8 (87.6,95.8)	95.1 (88.6,97.9)	94.5 (90.0,97.0)	96.2 (92.8,98)	92.6 (88.6,95.3)	94.6 (91.1,96.7)	
Type of patient									0.8187
CLD (No at risk)	120	83	103	65	98	141	157	195	
% (95% CI)	96.7 (91.3,98.7)	92.8 (84.6,96.7)	95.1 (88.7,97.9)	95.3 (86.1,98.5)	94.9 (88.1,97.8)	96.4 (91.7,98.5)	93.5 (88.2,96.5)	93.6 (88.6,96.5)	
HCC (No at risk)	52	83	58	33	73	84	75	81	0.2469
% (95% CI)	92.2 (80.5,97.0)	92.7 (84.5,96.7)	87.9 (76.3,94.1)	93.9 (77.9,98.4)	95.8 (87.6,98.6)	97.6 (90.8,99.4)	90.5 (81.2,95.4)	97.5 (90.5,99.4)	
VS (No at risk)	9	4	1	2	8	12	12	17	0.8854
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	87.5 (38.7,98.1)	91.7 (53.9,98.8)	100 (-)	94.1 (65.0,99.1)	
HCC downstaging (No at risk)	2	7	4	3	3	2	4	6	0.7300
% (95% CI)	100 (-)	85.7 (33.4,97.9)	100 (-)	100 (-)	100 (-)	50.0 (0.6,91.0)	75.0 (12.8,96.1)	83.3 (27.3,97.5)	
Recipient blood group									0.4282
O (No at risk)	95	78	67	48	86	111	119	124	
% (95% CI)	96.8 (90.5,99.0)	92.3 (83.6,96.5)	94.0 (84.9,97.7)	95.8 (84.2,98.9)	94.2 (86.6,97.5)	97.3 (91.9,99.1)	90.6 (83.7,94.7)	95.7 (89.8,98.2)	
A (No at risk)	67	72	78	46	74	90	92	133	0.9126
% (95% CI)	95.4 (86.5,98.5)	95.8 (87.6,98.6)	91 (82.0,95.6)	95.7 (83.7,98.9)	94.6 (86.1,97.9)	95.5 (88.5,98.3)	94.4 (87.0,97.6)	95.2 (89.6,97.8)	
B (No at risk)	18	20	18	7	22	33	33	33	0.9866
% (95% CI)	94.4 (66.6,99.2)	90.0 (65.6,97.4)	94.4 (66.6,99.2)	85.7 (33.4,97.9)	95.5 (71.9,99.3)	93.9 (77.9,98.4)	93.9 (77.9,98.4)	92.9 (74.2,98.2)	

AB (No at risk)	3	7	3	2	1	5	5	10	0.6615
% (95% CI)	66.7 (5.4,94.5)	71.4 (25.8,92.0)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	80 (40.9,94.6)	
Centre									
Newcastle (No at risk)	4	3	4	2	13	14	25	18	0.8930
% (95% CI)	100 (-)	100 (-)	100 (-)	100 (-)	100 (-)	92.9 (59.1,99.0)	91.8 (71.1,97.9)	100 (-)	
Leeds (No at risk)	26	20	21	15	16	26	35	17	0.4391
% (95% CI)	92.3 (72.6,98.0)	90.0 (65.6,97.4)	85.7 (62.0,95.2)	100 (-)	93.3 (61.3,99.0)	100 (-)	85.6 (68.8,93.8)	94.1 (65.0,99.1)	
Cambridge (No at risk)	30	37	31	29	43	52	47	57	0.7945
% (95% CI)	96.7 (78.6,99.5)	94.6 (80.1,98.6)	90.3 (72.9,96.8)	100 (-)	93 (79.9,97.7)	96.2 (85.5,99.0)	95.5 (83.2,98.9)	96.5 (86.7,99.1)	
Royal Free (No at risk)	13	28	36	11	22	18	30	44	0.6004
% (95% CI)	92.3 (56.6,98.9)	85.7 (66.3,94.4)	91.6 (76.1,97.2)	72.7 (37.1,90.3)	90.9 (68.3,97.6)	88.9 (62.4,97.1)	89.7 (71.4,96.6)	95.5 (83.0,98.8)	
Kings College (No at risk)	46	37	36	30	46	48	46	59	0.8989
% (95% CI)	95.5 (83.0,98.8)	94.6 (80.1,98.6)	97.2 (81.9,99.6)	93.1 (75.1,98.2)	100 (-)	95.8 (84.4,98.9)	95.7 (83.7,98.9)	96.2 (85.6,99.0)	
Birmingham (No at risk)	52	39	33	11	25	54	34	82	0.6494
% (95% CI)	96.2 (85.5,99.0)	92.3 (78.0,97.5)	97.0 (80.4,99.6)	100 (-)	96.0 (74.8,99.4)	98.1 (87.6,99.7)	91.2 (75.1,97.1)	92.7 (84.4,96.6)	
Edinburgh (No at risk)	12	13	5	5	18	27	32	23	0.2974
% (95% CI)	100 (-)	100 (-)	80.0 (20.4,96.9)	100 (-)	83.3 (56.8,94.3)	96.3 (76.5,99.5)	96.9 (79.8,99.6)	91.3 (69.5,97.8)	

3.8.4 **Figure 23** shows the unadjusted one-year transplant survival by time period and donor type for transplants performed in either the twelve months prior to NLOS or in the first eighty-four months of NLOS. Transplant survival was defined as the time from first transplant to retransplant, death or last known survival reported to NHSBT. Patients who received a second transplant or who died post-transplant were treated as events while patients who were alive with a functioning first transplant were censored at 1 year.

3.8.5 There were no statistically significant differences in the unadjusted one-year transplant survival between the time periods for DBD and DCD transplants (log-rank p-value=0.91 and 0.81).

Figure 23 Unadjusted one year transplant survival after first adult elective liver transplant from deceased donor, 20 March 2017 to 19 March 2025



4 CONCLUSIONS

The new National Liver Offering Scheme was implemented on the 20th March 2018 and updated on 4th October 2022. 6465 DBD and 7270 DCD livers were offered for transplantation in the first ninety six months of the scheme. For DBD donors, the proportion retrieved ranged between 85% and 93% in the 96 months post and 88% in the year prior to NLOS. The equivalent proportion for DCD was 26% to 57% for the 96 months post and 32% in the year prior to NLOS.

APPENDIX A: SUPER-URGENT CATEGORIES

INDICATION FOR REGISTRATION

- 1 - Category 1: Aetiology: Paracetamol poisoning: pH <7.25 more than 24 hours after overdose and after fluid resuscitation
- 2 - Category 2: Aetiology: Paracetamol poisoning: Co-existing prothrombin time >100 seconds or INR >6.5, and serum creatinine >300 µmol/l or anuria, and grade 3-4 encephalopathy
- 3 - Category 3: Aetiology: Paracetamol poisoning: Significant liver injury and coagulopathy following exclusion of other causes of hyperlactatemia (e.g. pancreatitis, intestinal ischemia) after adequate fluid resuscitation: arterial lactate >5 mmol/l on admission and >4 mmol/l 24 hours later in the presence of clinical hepatic encephalopathy
- 4 - Category 4: Aetiology: Paracetamol poisoning: Two of the three criteria from category 2 with clinical evidence of deterioration (eg increased ICP, FiO₂ >50%, increasing inotrope requirements) in the absence of clinical sepsis
- 5 - Category 5: Aetiology: Favourable non-paracetamol aetiologies such as acute viral hepatitis or ecstasy/cocaine induced ALF: the presence of clinical hepatic encephalopathy is mandatory and: prothrombin time >100 seconds, or INR >6.5, or any three from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; any grade of hepatic encephalopathy with jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 6 - Category 6: Aetiology: Unfavourable non-paracetamol aetiologies such as seronegative or idiosyncratic drug reactions: a) prothrombin time >100 seconds, or INR >6.5, or b) in the absence of clinical hepatic encephalopathy then INR >2 after vitamin K repletion is mandatory and any two from the following: age >40 or <10 years; prothrombin time >50 seconds or INR >3.5; if hepatic encephalopathy is present then jaundice to encephalopathy time >7 days; serum bilirubin >300 µmol/l
- 7 - Category 7: Aetiology: Acute presentation of Wilson's disease or Budd-Chiari syndrome. A combination of coagulopathy and any grade of encephalopathy
- 8 - Category 8: Hepatic artery thrombosis on days 0 to 21 after liver transplantation
- 9 - Category 9: Early graft dysfunction on days 0 to 7 after liver transplantation with at least two of the following: AST >10,000; INR >3.0; arterial lactate >3 mmol/l; absence of bile production
- 10 - Category 10: The total absence of liver function (eg after total hepatectomy)
- 11 - Category 11: Any patient who has been a live liver donor (NHS entitled) who develops severe liver failure within 4 weeks of the donor operation
- 20 - Category 20: Acute liver failure in children under two years of age: INR >4 or grade 3-4 encephalopathy. Definition: Multisystem disorder in which severe acute impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis in a child with no recognised underlying chronic liver disease. Children with leukaemia/lymphoma, haemophagocytosis and disseminated intra-vascular coagulopathy are excluded

APPENDIX B: THREE MONTH REGISTRATION OUTCOME

Figure B1 Three month registration outcome for active elective liver and liver/kidney patients, by type of patient, 20 December 2014 to 19 December 2025




Figure B2 Three month registration outcome for active elective liver and liver/kidney patients, by age group, 20 December 2014 to 19 December 2025




Figure B3 Three month registration outcome for active elective liver and liver/kidney patients, by first transplant or re-graft, 20 December 2014 to 19 December 2025






Figure B4 Three month registration outcome for active elective liver and liver/kidney patients, by sex, 20 December 2014 to 19 December 2025





APPENDIX C: SIX MONTH REGISTRATION OUTCOME

Figure C1 Six month registration outcome for active elective liver and liver/kidney patients, by type of patient,
20 September 2014 to 19 September 2025




Figure C2 Six month registration outcome for active elective liver and liver/kidney patients, by age group,
20 September 2014 to 19 September 2025




Figure C3 Six month registration outcome for active elective liver and liver/kidney patients, by first transplant or re-graft,
20 September 2014 to 19 September 2025




Figure C5 Six month registration outcome for active elective liver and liver/kidney patients, by quarter,
20 September 2014 to 19 September 2025




Table D.1 Median (IQR; range) time to transplant (days) for named patient offers for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026 **LAG(26)03**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Centre									
Newcastle (N)	-	20	21	21	20	13	13	13	9
Median (IQR)	-	43 (21.5, 97.5)	34 (16, 85)	40 (9, 136)	32.5 (12, 107.5)	8 (5, 12)	21 (9, 164)	29 (7, 56)	18 (2, 133)
Range	-	2 - 318	2 - 488	4 - 607	2 - 760	4 - 998	4 - 1233	4 - 485	2 - 181
Leeds (N)	-	58	60	54	52	69	62	65	55
Median (IQR)	-	41.5 (8, 130)	19.5 (8, 100.5)	25 (11, 105)	18.5 (9, 82)	21 (7, 124)	32 (11, 84)	57 (13, 164)	61 (24, 128)
Range	-	1 - 1341	1 - 662	1 - 1260	1 - 1187	1 - 1058	1 - 873	2 - 1454	2 - 1780
Cambridge (N)	-	49	42	21	38	35	46	34	29
Median (IQR)	-	31 (9, 67)	15 (5, 30)	11 (3, 23)	22.5 (6, 63)	14 (7, 62)	16 (8, 42)	14.5 (5, 68)	16 (7, 52)
Range	-	2 - 760	2 - 656	0 - 153	0 - 633	1 - 407	1 - 753	2 - 1285	2 - 1031
Royal Free (N)	-	67	61	41	57	50	44	43	46
Median (IQR)	-	20 (6, 100)	19 (8, 66)	27 (8, 74)	22 (5, 92)	27 (9, 78)	37 (8.5, 137)	23 (6, 94)	19.5 (7, 64)
Range	-	1 - 1261	1 - 971	2 - 669	2 - 592	2 - 1453	2 - 1004	1 - 985	1 - 456
Kings College (N)	-	110	111	90	104	84	80	67	84
Median (IQR)	-	37 (10, 235)	28 (7, 160)	26.5 (7, 131)	27 (8, 78)	64 (10, 260)	86.5 (23.5, 265)	83 (19, 377)	44.5 (8, 193.5)
Range	-	1 - 1711	1 - 1620	1 - 1687	1 - 968	2 - 2100	1 - 1286	1 - 1647	1 - 1503
Birmingham (N)	-	119	108	69	88	92	90	60	73
Median (IQR)	-	35 (9, 92)	40 (7.5, 156.5)	28 (5, 107)	23 (7, 80)	49.5 (14.5, 172.5)	49.5 (15, 226)	67 (13.5, 203.5)	63 (9, 225)
Range	-	1 - 1657	1 - 865	1 - 1814	1 - 1470	1 - 1066	1 - 811	1 - 1556	1 - 1324
Edinburgh (N)	-	68	38	48	36	35	27	33	29
Median (IQR)	-	16.5 (5, 102.5)	39 (17, 98)	23 (9, 229)	21 (7, 37)	21 (8, 78)	80 (32, 204)	31 (16, 109)	39 (9, 119)
Range	-	1 - 1124	2 - 640	1 - 694	1 - 452	2 - 218	3 - 1401	2 - 1274	1 - 988

Table D.2 Median (IQR; range) time to transplant (days) for fast-track offers for adult elective liver and liver/kidney transplants performed in the UK using livers from DBD donors, 20 March 2017 to 19 March 2026, as at 10 April 2026

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
Centre									
Newcastle (N)	-	2	5	6	3	1	4	8	2
Median (IQR)	-	50 (4, 96)	21 (14, 64)	121.5 (22, 190)	88 (62, 130)	231 (231, 231)	81.5 (32.5, 389.5)	59.5 (19, 126.5)	367 (70, 664)
Range	-	4 - 96	1 - 517	2 - 494	62 - 130	231 - 231	12 - 669	3 - 308	70 - 664
Leeds (N)	-	8	19	16	8	5	9	14	6
Median (IQR)	-	49.5 (21, 449)	93 (33, 187)	120.5 (61.5, 291)	119 (96.5, 170.5)	136 (46, 413)	206 (137, 414)	155 (81, 357)	95.5 (76, 732)
Range	-	6 - 566	3 - 1405	6 - 671	42 - 254	4 - 769	18 - 735	8 - 507	40 - 829
Cambridge (N)	-	16	18	14	12	5	6	11	9
Median (IQR)	-	65.5 (20.5, 258)	77 (15, 167)	46 (25, 212)	91 (56.5, 147)	16 (12, 139)	64.5 (5, 147)	69 (31, 237)	100 (77, 158)
Range	-	1 - 583	1 - 603	9 - 679	26 - 191	1 - 311	2 - 676	17 - 530	36 - 422
Royal Free (N)	-	16	30	16	8	18	24	30	19
Median (IQR)	-	106.5 (40, 244.5)	72.5 (37, 153)	61 (27, 260.5)	220.5 (86.5, 399)	112 (51, 440)	104 (34, 297.5)	100 (50, 278)	95 (22, 148)
Range	-	3 - 547	1 - 734	0 - 621	13 - 557	8 - 523	5 - 869	2 - 449	1 - 304
Kings College (N)	-	33	34	25	13	14	23	16	26
Median (IQR)	-	98 (29, 252)	97.5 (58, 193)	60 (19, 140)	107 (34, 315)	180.5 (111, 293)	145 (58, 263)	95 (33, 248.5)	109.5 (31, 311)
Range	-	1 - 605	6 - 465	0 - 512	3 - 689	4 - 1103	3 - 1105	7 - 1074	0 - 801
Birmingham (N)	-	35	46	45	39	23	20	19	15
Median (IQR)	-	93 (22, 150)	129 (32, 476)	194 (65, 405)	122 (33, 282)	260 (68, 500)	162 (104, 452.5)	375 (47, 549)	66 (11, 861)
Range	-	1 - 937	0 - 976	1 - 1593	1 - 1400	1 - 2223	30 - 1420	3 - 1400	5 - 1474
Edinburgh (N)	-	20	14	10	3	5	4	2	6
Median (IQR)	-	42.5 (12.5, 192.5)	106 (46, 178)	84 (52, 324)	13 (2, 51)	30 (23, 31)	29.5 (23.5, 84.5)	290 (150, 430)	34.5 (10, 180)
Range	-	2 - 621	10 - 310	4 - 749	2 - 51	6 - 57	18 - 139	150 - 430	8 - 581